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ABSTRACT 
Several recent reports from this laboratory demonstrate a regulatory role for 
intracellular Ca2+ ([Ca2+]i) in modulating lipid metabolism in both human and murine 
adipocytes, with increased [Ca2+]i coordinately stimulating lipogenesis and inhibiting 
lipolysis, thereby expanding lipid mass. Further, we have recently demonstrated that 
l,25-dihydroxyvitamin-D3 [1,25-(0H)2-D3] stimulates adipocyte membrane vitamin D 
receptor (m VDR)-mediated rapid Ca2+ influx into adipocytes, resulting in the stimulation 
of lipogenesis and inhibition of lipolysis. However, increasing [Ca2+]i in the early stages 
of differentiation inhibits human adipocyte differentiation, whereas increasing [Ca2+]; in 
the late stage promotes human adipocyte differentiation. Accordingly, we have 
investigated the role of l,25-(0H)2-D3 in the differentiation of 3T3-Ll preadipocytes, 
using triglyceride (TG) accumulation and glycerol-3-phosphate dehydrogenase (GPDH) 
as markers. 3T3-Ll preadipocytes were placed in differentiation media upon confluence, 
and exposed to varying amounts (0, lnM, and lOnM) of l,25-(0H)2-D3 for either one­
hour pulses or for sustained (24 hrs or 48 hrs) amounts of time throughout the 
differentiation process. Exposure to one-hour pulses of lnM 1,25-(0H)2-D3 throughout 
differentiation caused modest decreases (31 %-38%) in TG accumulation (p<0.0001), 
with one-hour pulse exposure to 1 OnM 1,25-(0H)2-D3 having little to no effect on TG 
accumulation. One-hour pulse exposure to both lnM and 1 OnM l ,25-(0H)2-D3 
suppressed GPDH activity early, but not late in differentiation. Sustained (24-hour) 
exposure to 1,25-(0H)i-D3 (lnM and lOnM) inhibited differentiation at 0-24 hrs, with 
decreases in both TG and GPDH of 41-81 % (p<0.0001). Similarly, sustained exposure 
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of l ,25-(0H)i-D3 resulted in marked inhibition of OPDH activity and TO accumulation 
early in differentiation. In contrast, sustained exposure late in differentiation exerted no 
significant effects on either marker of differentiation. PPAR-y and pref-I expression 
were also used as markers of differentiation. One-hour pulses of 1 OnM 1,25-(0H)i-D3 
did not cause any changes in PPAR-y expression compared to control. Sustained 
exposure to l ,25-(0H)2-D3 throughout differentiation decreased PPAR-y expression, 
with a 92% decrease from 0-48h (p<0.0001). One-hour pulses of 1,25-(0H)i-D3 had no 
effect on Pref-I expression, with the exception of an increase in expression at 4 7-48 hr 
(p<0.0001). Sustained exposure to lOnM 1,25-(0H)2-D3 at 0-48 hrs, 24-48 hrs and 47-
48 hrs all caused significant increases ( 125%-146%) i� the expression of Pref-I 
(p<0.001). Thus, although 1,25-(0H)2-D3 stimulates lipogenesis, inhibits lipolysis and 
increases TO accumulation in mature human and murine adipocytes, it also modestly 
inhibits the differentiation of preadipocytes into mature adipocytes. 
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PARTl 
INTRODUCTION 
I 
INTRODUCTION 
Intracellular calcium ([Ca2+]i) plays a key role in the metabolic modifications 
associated with obesity (1). Studies involving the mechanisms of agouti gene-induced 
obesity found that [Ca2+]i modulates de novo lipogenesis in both human and murine 
adipocytes. Previous studies show that an increase in [Ca2li via receptor or voltage­
mediated calcium channels stimulates the expression and activity of fatty acid synthase 
(FAS), a key enzyme in de novo lipogenesis, thereby causing an increase in lipogenesis 
and a decrease in lipolysis. The resulting triglyceride accumulation leads to adipocyte 
hypertrophy (2). 
[Ca2li also appears to play a role in the regulation of adipogenesis, a contributing 
factor to both human and murine obesity (3). In order to investigate the specific role of 
calcium, both thapsigargin, a Ca2+-ATPase inhibitor, and A23187, a calcium ionophore, 
were used as calcium agonists to stimulate an increase in [Ca2Ji in human preadipocytes. 
Exposure early in differentiation suppressed triglyceride accumulation greatly. However, 
increasing [Ca2+]i late in differentiation increased triglyceride accumulation. Similar 
results were also seen using KCl and agouti protein as [Ca2Ji agonists (2, 3). Therefore, 
increasing [Ca2+]i has a biphasic effect on human adipocyte differentiation, with an 
increase early inhibiting differentiation and an increase in the late stages stimulating 
adipocyte differentiation and lipid filling (3). 
Recent studies have introduced a paradox by showing that a decrease in the 
expression of genes normally involved in adipogenesis is associated with obesity and 
diabetes mellitus. White adipose tissue from obese mice exhibited decreased expression 
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of genes important in adipocyte differentiation, as compared to the lean controls. Sterol 
responsive element binding protein (SREBP), responsible for positively regulating 
multiple genes coding for lipogenic enzymes, demonstrated a 2.7-fold decrease in 
expression. Several mRNAs that encode proteins involved in lipid metabolism were 
decreased, including glycerol 3-phosphate dehydrogenase and stearoyl CoA desaturase. 
A dedifferentiation was observed in 3T3-Ll adipocytes including a suppression of 
PP ARy and C/EBPa., as well as other lipogenic enzymes in response to tumor necrosis 
factor a and transforming growth factor f3 ( 4 ). 
1,25-dihydroxyvitamin D3 [l ,25-(0H)2-D3] acts as a calcium agonist (5). Further, 
we have recently demonstrated that l ,25-(0H)2-D3 stimulates adipocyte membrane 
vitamin D receptor (m VDR)-mediated rapid Ca2+ influx into adipocytes, resulting in the 
stimulation of lipogenesis and inhibition oflipolysis (5). This effect was mimicked by 
la,25-(0H)2-lumisteroh, an agonist for the mVDR. These effects were not seen when 
the human adipocytes were pretreated with 1 P,25-dihydroxyvitamin D3, a specific 
antagonist for mVDR. l,25-(0H)2-D3 was also shown to increase adipocyte fatty acid 
synthase (FAS), with la,25-(0H)2-lumisteroh having a greater stimulatory effect on FAS 
activity. Pretreatment with I f3,25-dihydroxyvitamin D3 also prevented the stimulation of 
FAS. 1,25-(0H)i-D3 and la,25-(0H)i-lumisteroh also reduced adipocyte basal lipolysis, 
with 1 �,25-dihydroxyvitamin D3 preventing any inhibition of lipolysis ( 5). In addition, 
Norman et al. (6) demonstrated that l a,25-dihydroxylumisteroh acts on the mVDR solely 
to generate non-genomic action in adipocytes, while 1,25-(0H)i-D3 may target both the 
mVDR and the nuclear vitamin D receptor (nVDR) to mediate genomic and non-genomic 
actions which may interact with each other in signal response and, thereby compromise 
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the modulation of lipid metabolism. Accordingly, we have investigated the role of l ,25-
(0H)2-D3 in adipogenesis. 
4· 
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PART2 
LITERATURE REVIEW 
I. Adipocyte Differentiation 
A. Models of adipocyte differentiation 
While the developmental origins of adipocytes are poorly understood, it is known 
that the transformation of a fertilized egg to the determination and conversion of 
precursor cells into mature adipocytes occurs in a series of stages. Pluripotent fibroblasts 
( stem cells) differentiate into multi potential mesenchymal precursors which may become 
preadipocytes, chondroblasts, osteoblasts, or myoblasts ( 1, 2). In a human model, 
preadipocytes begin to differentiate into adipose tissue during late embryonic 
development, with the majority of the conversion taking place shortly after birth (3). The 
preadipocytes in rodent and murine models do not begin to differentiate into adipose 
tissue until after birth ( 4 ). Depending on energy needs, all species have the ability to 
differentiate preadipocytes throughout their lives. 
1. In vivo models of adipocyte differentiation 
In vivo study of adipocyte differentiation is difficult due to the complexity of 
adipose tissue. Adipocytes account for only one third of fat tissue, with the remaining 
two thirds consisting of blood vessels, nerve tissue, fibroblasts, and preadipocytes in 
various stages of development (2). Comprehensive in vivo studies are confounded by the 
difficulty distinguishing preadipocytes from fibroblasts and the inability to coordinate 
preadipocytes at similar stages of development. 
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2. In vitro models of adipocyte differentiation 
a. Primary cultures of preadipocytes 
Primary preadipocytes have been successfully obtained from multiple species 
including rats, mice, rabbits, pigs, and humans. Because the stage of differentiation and 
the lineage of preadipocyte cell lines have not been well established, primary cultures can 
be useful for validating results from preadipose cell lines. The use of primary culture has 
several advantages over preadipocyte cell lines. While cell lines are aneuploid, the 
diploid primary cells are a better representation of an in vivo situation. Another 
advantage is the ability of primary cultures to be derived from fat tissue obtained from 
various species at different postnatal stages of development and from multiple adipose 
depots. Primary cultures can come from subcutaneous, epididymal, and perirenal fat 
stores (1). There are also several drawbacks of primary cultures. First, large amounts of 
adipose tissue are required due to the small amount of preadipocytes that make up the 
total fat tissue. Second, it is difficult to isolate preadipocytes from other fibroblast-like 
cells that are found in adipose tissue. Finally, primary cultures have a limited life span in 
culture (2). 
b. Cell lines of preadipocytes 
There are advantages and disadvantages to using a cell line to study preadipocyte 
differentiation. It can be advantageous to uses a cell line which is homogenous in cells 
that are all at the same stage of differentiation. This allows for detailed responses to 
treatments during differentiation. Another advantage is the ability of cell lines to provide 
a consistent source of preadipocytes because of their ability to be passaged indefinitely. 
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There is some variation in the differentiation requirements of each cell line depending on 
the developmental stage at which the cells were arrested and derived (2,5). A major 
disadvantage to using a cell line is the lack of multiple factors that are seen in whole 
tissue in vivo. Cell lines are unable to give a realistic view of true physiological 
conditions. 
{I) Pluripotent fibroblasts 
Pluripotent fibroblasts (l OTl/2, Balb/c 3T3, 1246, RCJ3. l and CHEF/18 
fibroblasts) can be converted into several cell types. lOTl/2 fibroblasts, derived from 
C3H mouse embryos (6), may be converted to preadipose, premuscle, and precartilage 
tissue. Pluripotent fibroblasts are good models for understanding the events that lead to 
cellular determination. 
{2) Unipotent preadipocytes 
Unipotent preadipocytes (3T3-Ll ,  3T3-F422A, 1246, Obl 7, TAI,  and 30A5) are 
committed and can either remain as preadipocytes or differentiate into adipocytes. These 
cell lines are useful when studying the conversion of preadipocytes to adipocytes. The 
most widely used cell lines are 3T3-Ll and 3T3-F422A, which were isolated from Swiss 
3T3 cells derived from disaggregated 17 to 19 day mouse embryos (7). Ob 17 cells were 
derived from the epididymal fat pads of genetically obese (ob/ob) adult mice and are used 
to explore differentiation resulting from genetic obesity (8). 
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B. Process of differentiation of 3T3-Ll preadipocytes 
The 3T3-Ll cell line is one the most well studied models of adipocyte 
differentiation. When injected into mice, 3T3-Ll preadipocytes form fat pads that are 
indiscernible from the normal fat tissue (9). The development of fat droplets mimics the 
actions of live adipose tissue (10). 
3T3-Ll cells spontaneously differentiate into fat-cell clusters over a period of 
several weeks when cultured in fetal calf serum. This process can be accelerated when 
confluent 3T3-Ll preadipocytes are exposed to an adipogenic cocktail. This cocktail 
contains a glucocorticoid, a phosphodiesterase inhibitor, and fetal bovine serum. Insulin 
has also been used in combination with the above and works via the insulin-like growth 
factor 1 (IGF-1) receptor. Dexamethasone (DEX) is a synthetic glucocoticoid agonist 
commonly used in a differentiation cocktail. Methylisobutylxanthine (MIX) is a 
phosphodiesterase inhibitor used to increase the intracellular cAMP levels in the 
adipogenic cocktail ( 1 ). 
Twenty-four hours after the introduction of a differentiation cocktail, the 
preadipocytes experience a postconfluent mitosis and an ensuing growth arrest (11 ). The 
preadipocytes go through at least one round of DNA replication and cell division. The 
mitosis is believed to be needed to unwind DNA and allow the transcription factors 
access to transactivate adipocyte specific genes (5). Day 2 marks the end of the 
postconfluent mitosis and the beginning of a growth arrest called Go ( 12). After growth 
arrest, the preadipocytes are ready for differentiation and are committed to the formation 
of adipocytes. On day 3, growth-arrested cells begin to express late markers of 
differentiation such as multiple proteins that modulate adipocyte metabolism as well as 
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lipogenic and lipolytic enzymes. 3T3-Ll cells accumulate fat droplets and become 
spherical in appearance by day 5 to 7. 
C. Changes during the differentiation of preadipocytes 
While the 3T3-Ll cells have been heavily analyzed, the exact chronology of the 
earliest stages of adipocyte differentiation is still unknown. Growth arrest triggers the 
expression of lipoprotein lipase (LPL) mRNA in 3T3-Ll preadipocytes (2,5). While the 
presence of LPL has been thought to be an early sign of adipocyte differentiation, the 
expression of LPL occurs upon confluence independent of the addition of a 
differentiation cocktail. LPL is also found in other mesenchymal cell types and is 
therefore not adipocyte specific. These two properties leave LPL' s role as an early 
marker of adipocyte differentiation ambiguous (1 ). 
Within the first hour of differentiation, the expression of c-fos, c-jun,junB, and c­
myc is seen (5). Fos and jun proteins have not been linked to any differentiation-specific 
events, but are believed to have mitogenic properties. c-myc has been shown to initiate 
mitogenesis in differentiating preadipocytes (5). The expression of the above proteins 
depletes 2-6 h after the initial exposure to the differentiation cocktail (2). 
There are at least two families of transcription factors, CCAAT/enhancer binding 
proteins (C/EBP) and peroxisome proliferator-activated receptors (PP AR), which are 
induced early during adipocyte differentiation. C/EBP-P and C/EBP-o are the first 
transcription factors induced in the differentiation process. The expression of these 
factors, controlled by exogenous differentiation promoters, induces and increases 
adipogenesis in response to hormones. C/EBP-P is responsive to DEX, while C/EBP-o 
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responds to MIX (13). The activity of C/EBP-P and C/EBP-o is thought to mediate the 
expression of PPAR-y (14). PPAR-y is largely adipocyte specific and is expressed at 
low, but detectable levels in preadipocytes. Its expression quickly increases once 
exposed to hormonal induction of differentiation. It is transcriptionally induced on day 2 
of differentiation with maximum levels of expression seen in mature adipocytes (1, 15). 
The decrease of C/EBP-P and C/EBP-6 expression in the early to mid stages of 
differentiation is followed by an increase in the expression of C/EBP-a. which occurs 
directly before the expression of adipocyte-specific genes (15) (Fig. I). 
Stem Cell 
n Early 
n Late 
Pref- 1 
I IC/EBPP 
PPARy 
C/EBPa 
dipocyte Genes 
ipogenic Enzymes 
FA Binding Proteins 
Figure 1. The process of differentiation from a multipotential stem cell to a mature, lipid 
filled adipocyte. Selected molecular events accompanying this process are indicated to 
the right, with their duration reflected by a solid line. · Pref-1, preadipocyte factor- I ;  
C/EBP, CCAT/enhancer -binding protein; PPAR-y, peroxisome proliferator-activated 
receptor-y; FA, fatty acid. 
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It appears PPAR-y and C/EBP-a alone or in cooperation induce the transcription 
of many adipocyte genes encoding proteins and enzymes involved in creating the 
adipocyte phenotype. Once induced, PP AR-y and C/EBP-a appear to cross-regulate each 
other to maintain their gene expression levels, although C/EBP-� and C/EBP-o levels 
decrease after early transient expression (16). It is thought that an adipocyte-specific 
control of terminal differentiation might be found in PPAR-y and C/EBP-a. While both 
are important for the late stages of differentiation in a synergistic manner, neither factor 
is expressed at high levels in preadipocytes, and therefore cannot be involved in early 
development. While coexpression promotes the differentiation process, ectopic 
expression of either factor does not promote differentiation to the same extent (1 5). 
Sterol regulatory element binding protein-1/adipocyte determination and 
differentiation factor- I (SREBP- 1/ ADD 1) is another transcriptional factor that is induced 
early in adipocyte differentiation. This factor appears to up-regulate PPAR-y expression 
(17). 
Preadipocyte factor- I (pref- 1 )  is an inhibitor of adipocyte differentiation. It is 
thought to play a role in maintaining preadipocyte phenotype. A decrease in pref- 1  
expression is seen during adipocyte differentiation. It is abundant in preadipocytes, but is 
undetectable in adipocytes. It is the only known gene whose expression is completely 
down-regulated during adipocyte differentiation ( 1 ). 
As adipocytes enter the terminal phases of differentiation, they express an 
increase in lipogenesis and become sensitive to insulin. The activity, protein, and mRNA 
levels of enzymes found during triacylglycerol (TAG) metabolism increase 10 to 100 
fold. These enzymes include ATP citrate lyase, malic enzyme, acetyl-CoA carboxylase, 
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stearoyl-CoA desaturase-1 (SCD-1 ), glycerol-3-phosphate acyltransferase, glycerol-3-
phosphate dehydrogenase, fatty acid synthase, and glyceraldehyde-3-phosphate 
dehydrogenase ( 1  ). 
1 .  Transcriptional control of adipocyte differentiation 
a. Peroxisome proliferator-activated receptor (PP AR) family 
The PP ARs belong to a type II nuclear hormone receptor family and form 
heterodimers with the retinoid X receptor (RXR) ( 18). The PP ARs regulate transcription 
through binding of PPAR-RXR heterodimers to a response element consisting of a direct 
repeat of the nuclear receptor hexameric DNA recognition motif spaced by one 
nucleotide { 19). There are three known members of the PPAR family, including PPAR­
a, PPAR-6, and PPAR-y. PPAR-a is weakly expressed in adipocytes. While PPAR-6 is 
not adipocyte specific, it is highly expressed in adipose tissue. Unfortunately, its role in 
adipose tissue development has not yet been demonstrated. PPAR-r is the most adipose­
specific of the PP ARs, and it is induced before transcriptional activation of most 
adipocyte genes. Low but detectable expression of PP AR-r is also seen in the liver and 
hematopoietic cells (20). The PPAR-r gene gives rise to two isoforms, yl and y2. 
PPAR- y2 is highly enriched in adipose tissue and mediates gene expression regarding 
fatty acid metabolism (2 1 ). PP AR-y plays a key role in the transcriptional control of 
adipocyte-specific gene expression, including aP2, PEPCK, LPL, GLUT-4, and leptin 
( 1 ). 
The binding of ligands to PP AR-r enhances its transcriptional activity. 
Thiazolidinediones (TZDs) are synthetic ligands used to increase insulin sensitivity 
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clinically. These compounds bind to PPAR-y with high affinity and increase its 
transcriptional activity (22). 15-deoxy-0-PGJi is an endogenous ligand for PP AR-y ( l )  
PPAR-y plays an important role in the transcriptional control of adipogenesis. 
PP AR-r is expressed at low, but detectable levels in preadipocytes, with its expression 
increasing early in adipocyte differentiation (19). Retroviral expression of PPAR-y in 
fibroblasts causes an adipocyte phenotype to appear, including morphological changes, 
lipid accumulation, and adipocyte-specific gene expression. However, a point mutation 
in the zinc finger of PPAR-y required for DNA binding ablated its ability to induce 
differentition (23). 
The role of PPAR-y in adipogenesis has been demonstrated in PPAR-y knockout 
mice. The homozygous null mutation is lethal in gestation, resulting from a placental 
dysfunction (24, 25). Chimeric embryos were created using a combination of wild-type 
tetraploid cells which contribute to the development of extraembryonic tissues. One 
PP AR-y-null homozygous mutant developed to term, but died by postnatal day 5 from a 
variety of metabolic disorders. This animal lacked adipose tissue, suggesting that PP AR­
'Y is required for adipose tissue development in vivo (24). Chimeric mice were also 
created from both wild-type embryonic stem (ES) cells and PP AR-y-1· ES cells (26). In 
these mice, PP AR-y null ES cells do not contribute to the formation of adipose tissue, but 
do participate in the development of the other tissues. This study shows that PPAR-y is 
required for the in vitro differentiation of adipocytes from ES cells in addition to its 
adipogenic role in vivo. 
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b. CCAAT/enhancer binding protein (C/EBP) family 
C/EBP proteins were the first transcription factors demonstrated to play an 
important role in adipocyte differentiation. These transcription factors contain a basic 
transcriptional activation domain and a leucine zipper motif, which allows for homo- and 
heterodimerization. C/EBPs are not limited to adipose tissue, but rather are also found in 
other tissues, such as the liver, that metabolize lipids at high rates (1, 27). 
The expression of C/EBPs during adipocyte differentiation exhibits a distinct 
pattern, with C/EBP-P and C/EBP-6 expressed early in response to hormone stimulation 
and C/EBP-a expressed immediately before the induction of most adipocyte-specific 
genes (15). In fact, several adipocyte-specific genes, such as SCD-1, GLUT-4, aP2, 
PEPCK, leptin, and the insulin receptor, contain C/EBP-a binding sites in their promoter 
regions (1, 28). 
Ectopic expression of C/EBP-� is sufficient to induce differentiation of 3T3-Ll 
cells in the absence of hormone stimulation, while hormonal stimulation is required to 
induce differentiation in 3T3-Ll cells that over express C/EBP-6, but adipogenesis in 
these cells is accelerated (29). Constitutive expression of C/EBP-a is sufficient to induce 
differentiation of 3T3 -L l cells in the absence of hormonal agents, and the expression of 
antisense C/EBP-a mRNA inhibits differentiation of cultured preadipocytes (21, 30). 
C/EBP-a has been shown to promote adipogenesis in a variety of mouse fibroblasts, 
including those that have little or no spontaneous capacity to develop into adipocytes 
(31 ). The autoactivation of the C/EBP-a gene seems to play a role in the maintenance of 
the adipocyte phenotype. 
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Mouse models lacking C/EBPs demonstrate the importance of these transcription 
factors in adipose tissue development. Mice lacking either C/EBP-P or C/EBP-o usually 
survive without significant developmental of physiological defects. They develop normal 
white adipose tissue (WA n, but their brown adipose tissue (BAT) has a reduction in TG 
accumulation and UCP-1 expression. The double knockout mice have a very low 
survival rate (15%), but they exhibit a reduction in both WAT and BAT. The reduction 
in BAT is a result of decreased lipid accumulation, while decreased cell number causes 
the reduction in WAT (32). C/EBP-a knockout mice do not develop subcutaneous 
inguinal WAT (33). A high percentage of C/EBP-a deficient mice die from 
hypoglycemia that results from a failure to perform hepatic gluconeogenesis. The 
deficiency of C/EBP-a in the liver prevents it from regulating the genes involved in 
energy metabolism including glucose (33). All of these models illustrate the importance 
role the C/EBP family plays in adipogenesis. 
c. Sterol regulatory element binding protein-1/adipocyte determination and 
differentiation factor- I (SREBP1/ADD1) 
SREBP1/ADD1 is a group of basic helix-loop-helix (bHLH) leucine zipper 
transcriptional factors (1). The SREBP family consists of three members, SREBP-la, le, 
and 2. SREBP-1 a and 1 c are generated from the same gene in both human and murine 
models (34). ADDI, cloned from a rat cDNA library, is a homologue of human SREBP­
l c  (35). 
SREBP1/ADD1 has been shown to regulate a number of genes involved 
cholesterol and fatty acid metabolism (1 ,  21). SREBP1/ADD1 is an inactive molecule 
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bound to the membrane of the endoplasmic reticulum. Once cells sense a decrease in 
cholesterol, SREBPI/ADDI undergoes proteolytic cleavage and translocates to the 
nucleus to regulate the expression of target genes (36). While all of the SREBPs are 
capable of regulating similar gene expression, regulation of fatty acid biosynthesis is 
mediated primarily by SREBP-la and SREBP-lc/ADDI.  In vivo, adipose tissue 
expresses predominantly SREBP-lc/ADDI over other forms of SREBP (21). Expression 
of a dominant negative form of SREBP-1 c/ ADD I suppresses the expression of adipocyte 
marker genes and represses 3T3-Ll preadipocyte differentiation (37). Overexpression of 
SREBP-lc/ADDl in preadipocytes increases the transcriptional activity of PPAR-y by 
increasing the endogenous ligands (3 8). 
2. Hormonal control of adipocyte differentiation 
a. Insulin and insulin-like growth factor- I {IGF-1) 
Addition of insulin to differentiation media can promote adipogenesis and 
increase lipid accumulation in adipocytes (39). While preadipocytes express few insulin 
receptors, insulin may act by binding to the IGF-1 receptor (1). This may explain why 
pharmacological doses of insulin are required to achieve stimulatory effects on 
adipogenesis. 
IGF-1 is an essential factor for 3T3-Ll adipocyte differentiation. It is a critical 
component of fetal bovine serum for adipocyte differentiation, or it can be supplemented 
to enable differentiation to occur in a serum free environment. IGF-1 has a dose­
dependent action on 3T3-Ll preadipocyte differentiation under both serum-containing 
and serum-free conditions (40). 
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Insulin and IGF-1 may stimulate adipogenesis by activating downstream signal 
tranduction. Activation of ras by insulin or IGF-1 has been shown to mediate the 
stimulatory effects on adipogenesis. This was confirmed when it was shown that ectopic 
expression of ras promotes adipogenesis in the absence of hormonal stimulation ( 41 ). In 
addition, inactivation of ras inhibits adipogenesis. The timing of ras activation during 
differentiation is important in determining whether it will exhibit a stimulatory or 
inhibitory effect on differentiation. Ras is a small G protein that is also a mediator of the 
mitogen-activated protein kinase (MAPK) pathway, whose activation inhibits 
differentiation (42). IGF-1 and insulin also activate another down-stream signal, a 
serine/threonine kinase Akt (PKB) which is involved in adipocyte differentiation. 
Expression of constitutively active Akt/PKB in 3T3-Ll  cells induces spontaneous 
differentiation ( 1  ). 
b. Tumor necrosis factor-a (1NF-a) 
1NF-a is a potent inhibitor of adipocyte differentiation. It also suppresses the 
expression of some adipocyte-specific gene expression and decreases lipid accumulation 
in newly differentiated adipocytes, serving to dedifferentiate these cells (43, 44). This 
inhibitory effect on adipogenesis is mediated by down-regulation of C/EBP-a and PPAR­
'Y· This may explain the down-regulation of those adipocyte-specific genes, such as aP2 
and GLUT4, both of which contain binding sites for C/EBP-a and PPAR-y in their 
promoters. While these "dedifferentiated" cells may appear similar to preadipocytes, the 
expression of pref-1 is not restored in 1NF-a treated adipocytes. Pref-1 expression is 
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therefore a fundamental difference between naive preadipocytes and those that result 
from 1NF-a. treatment (43). 
c. Nuclear hormone superfamily 
The members of the nuclear hormone superfamily that influence adipocyte 
differentiation include glucocorticoids, 3,3 ',5-triiodothyronine (T3), and retinoic acid 
(RA). It is believed that these hormones act on differentiation via activating nuclear 
hormone receptors, including PPAR-y. 
DEX, a synthetic glucocorticoid, is used to induce differentiation in 3T3-L l cells. 
The addition of DEX to a differentiation cocktail is either required for differentiation or is 
used to accelerate the differentiation procees, depending on the origin of the cells. DEX 
has been shown to induce C/EBP-6 expression in 3T3-Ll cells. This increase may 
contribute to the formation of C/EBP-6/C/EBP-� heterodimers, which may lead to PP AR­
Y expression (1 ). DEX has also been shown to promote adipogenesis by inhibiting pref- I 
expression ( 45). 
RA inhibits adipocyte differentiation when administered in pharmacological 
doses. The inhibitory effect of RA on adipogenesis is mediated by the inhibition of the 
expression of C/EBP-�, C/EBP-a, and PPAR-y. Physiological doses of RA increases 
adipogenesis. The addition of RA either before or after treatment of inducing agents does 
not affect differentiation, suggesting that RA acts early in differentiation (1 ). 
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d. Prostaglandins 
Both mature adipocytes and cultured preadipocytes produce large amounts of 
prostaglandins (PGs), including PGF2a, PGE2, PGD2, amd PGii. PGE2 is a potent 
antilipolytic compound, suggesting that it may contribute to lipid accumulation in 
terminal adipogenesis. PGD2 and its derivative, PGJi, are endogenous ligands for PP AR­
'Y and �erefore act as adipogenic signals ( 46). Prostanoid FP receptor agonists have been 
shown to be potent inhibitors of the differentiation of 3T3-Ll cells. FP receptor 
stimulation causes a transient increase in intracellular Ca2+, activation of 
calcium/calmodulin dependent protein kinase (CaM), and an increase in DNA synthesis 
that is associated with the inhibition of differentiation. The addition of a CaM kinase 
inhibitor in the presence of an FP receptor agonist reverses the inhibition of 
differentiation and suggests an important role for CaM kinase in adipocyte differentiation 
(47). PGii is an agonist for PPAR-a, PPAR-o, and PPAR-y, suggesting that it may exert 
its adipogenic effect by the activation of the PP ARs ( 48). The role of PGE2 and PGD2 in 
adipocyte differentiation is not clear at this time. 
e. Intracellular secondary messengers 
cAMP, G proteins, and intracellular Ca2+ ([Ca2+]i) are all important in adipocyte 
differentiation. The role of cAMP in adipogenesis has been demonstrated by the use of 
MIX in adipocyte differentiation. MIX has been shown to increase the expression of 
C/EBP-�. MIX causes intracellular cAMP accumulation by inhibiting phosphodiesterase 
and stimulating adenylyl cyclase activity by blocking protein Gi (1  ). Studies have shown 
that synthetic cAMP analogs can replace MIX in differentiation cocktail, and increasing 
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cAMP through activation of adenylyl cyclase by forskolin can induce differentiation 
without MIX ( 49). 
The G proteins, Gsa and Gia, have been shown to play an important role in the 
differentiation of 3T3-Ll cells independently of adenylyl cyclase. Either suppression of 
Gsa by Gsa antisense knockout or ectopic expression of constitutively active Gia 
dramatically accelerated adipogenesis. These effects were exerted at ambient or elevated 
levels of cAMP, confirming that their effects on adipogenesis were independent of 
adenylyl cyclase (50). Further evidence confirmed this idea by demonstrating that the 
specific domains of Gsa and Gia responsible for adipogenesis are distinct from those 
interacting with adenylyl cyclase (51). 
[Ca2+] i is also important in cellular signaling and adipogenesis. Increasing [Ca2li, 
by either inhibiting Ca2+ -ATPase or stimulating Ca2+influx, inhibits the early stages of 
murine adipocyte differentiation. [Ca2+]i exerted this inhibitory effect by blocking the 
postconfluent mitotic phase and mediating sustained levels of c-myc expression (52). As 
mentioned earlier, the stimulation of the FP receptor by PGF2a causes an increase in 
[Ca2+] i, activating CaM and causing an inhibiton of adipocyte differentiation. This anti­
adipogenic effect can be reversed by the addition of a CaM kinase inhibitor (47). Recent 
data confirm that increasing [Ca2+] i exerts a biphasic regulatory role in human adipocyte 
differentiation, serving to inhibit the early stages of differentiation, while promoting the 
later stages of differentiation and lipid accumulation (53). The exact mechanism 
whereby [Ca2+] i undergoes this transition is unknown. Increasing cAMP promotes 
adipocyte differentiation, while it inhibits the expression and activity of fatty acid 
synthase, a key enzyme in de novo lipogenesis, and stimulates lipolysis in mature 
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adipocytes (54). There is a significant interaction between calcium and cAMP signaling 
pathways. Studies have shown that adenylyl cyclases are associated with the site of Ca2+ 
entry into the cell, and Ca2+ influx causes an inhibition of type V and VI adenylyl 
cyclases. This results in a reduction of cAMP levels (55). Alternatively, other data has 
demonstrated that increasing adipocyte [Ca2Ji stimulates phosphodiesterase 3B activity, 
resulting in a reduction of cAMP levels (56). Accordingly, increasing [Ca2+] i  in the early 
stages of differentiation may suppress preadipocyte cAMP levels and thereby inhibit 
differentiation. In contrast, a [Ca2+]i-induced decrease in cAMP late in differentiation up­
regulates lipogenesis and down-regulates lipolysis, promoting late adipocyte 
development and lipid accumulation. 
3. Preadipocyte factor-I (pref- I) control of adipocyte differentiation 
Pref-I is an inhibitor of adipogenesis. It is an EGF repeat-containing 
transmembrane protein that may link extracellular adipocyte differentiation signals to the 
interior cell (57). Expression of pref-I in 3T3-Ll preadipocytes decreases to 
undetectable levels during differentiation. Down-regulation of pref- 1  is required for 
adipogenic conversion, while constitutive expression of pref-I inhibits differentiation. 
This was confirmed by demonstrating that the exposure of antisense pref-I to 
preadipocytes markedly increases adipogenesis ( 45). Wnt signaling maintains 
preadipocytes in an undifferentiated state through the inhibition of the expression of 
PPAR-y and C/EBP-a. Correspondingly, disruption of Wnt signaling increases 
adipogenesis (58). 
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II. Regulation of Metabolism in Adipocytes 
Adipose tissue is a specialized connective tissue designed for synthesis, storage, 
and hydrolysis of triacylglycerols (TAGs). Triglycerides are stored as liquid droplets in 
the cytoplasm with an average half-life of only a few days. Thus, in a homeostatic 
situation, there is a continuous synthesis and breakdown of TAG in adipose tissue. The 
triglycerides found in adipocytes are derived from circulating lipoproteins or synthesized 
via de novo lipogenesis. De novo lipogenesis refers to the conversion of glucose to TAG. 
When energy is needed, TAG can also undergo lipolysis to release these fatty acids. 
A. De novo lipogenesis 
There are several steps involved in de novo lipogenesis. First, glucose undergoes 
glycolysis to produce pyruvate, which can then be oxidized by glycolytic enzymes to 
form acetyl-CoA. Citrate synthase converts acetyl-CoA into citrate which can then �e 
transported from the mitochondria to the cytosol. ATP-citrate lyase converts citrate back 
into acetyl-CoA which is converted into malonyl-CoA by acetyl-CoA carboxylase 
(ACC). The formation of malonyl-CoA is the rate limiting step of fatty acid synthesis. 
Fatty acid synthase (FAS) catalyzes the subsequent synthesis of palmitate from acetyl­
CoA and malonyl-CoA using nicotinamide adenine dinucleotide phosphate (NADPH) as 
a reducing equivalent. NADPH is derived from malic enzyme converting malate to 
pyruvate, or by the pentose phosphate pathway where glucose-6-phosphate is converted 
by glucose-6-phosphate dehydrogenase and 6-phosphogluconate is converted by 6-
phosphogluconate dehydrogenase. ACC and FAS are two key enzymes in de novo 
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lipogenesis. ACC catalyzes the rate-limiting reaction in fatty acid synthesis, while FAS 
catalyzes the subsequent synthesis of palmitate. The activity of ACC is regulated by 
short-term allosteric modification or covalent phosphorylation. FAS, however, is 
regulated at the transcriptional level, resulting in changes in FAS protein amount (59, 60). 
Humans exhibit lower FAS activity in both liver and adipose tissue compared to 
rodents. This may be attributed to the lower metabolic rate in humans compared to 
rodents ( 61 ). Human adipocytes contain substantial levels of FAS expression and 
activity which is sensitive to both nutritional and hormonal modulation (62, 63). Studies 
in humans given a high carbohydrate diet demonstrate that adipose tissue plays an 
important role in fat synthesis under these diets (64, 65). Adipocyte FA� expression and 
activity are elevated in genetic obesity ( 66). Thus, up-regulation of adipocyte de novo 
lipogenesis may contribute to obesity. 
1. Fatty acid synthase (FAS) 
The FAS found in E. coli and higher plants consists of seven separate 
polypeptides that are tightly associated in a single, organized complex (67). However, 
FAS found in vertebrates is comprised of a single, large peptide. From its N-terminus to 
its C-terminus, the amino acids encoding �-ketoacyl synthatase, acetyl-CoA tmsacylase, 
molonyl-CoA transacylase, dehygratase, enoyl reductase, ketoacyl reductase, acyl carrier 
protein, and thioesterase are organized into discrete domains. Active FAS is a 
homodimer with two identical 250 kDa subunits (68). 
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2. Nutritional, hormonal, and transcriptional regulation of fatty acid synthase 
FAS is very sensitive to changes in nutritional status. In rats, the fasting state 
exhibits a decrease in the synthesis of FAS, while refeeding a high carbohydrate/low fat 
diet after fasting increases FAS synthesis by 20-25 fold (69): Using the same starvation 
and refeeding approach in mice produced an increase in FAS expression by up to 3 9 fold 
(70). This fasting/refeeding model alters the circulating glucose level, which induces the 
secretion of hormones mediating de novo lipogenesis. These hormones will be discussed 
later. 
Carbohydrates play an important role in regulating FAS. Experiments in 
hepatocytes and adipocytes demonstrate that glucose stimulates the transcription of 
lipogenic genes including FAS (60). However, 3-0-methylglucose, a glucose analogue 
transported into the cell but not phosphorylated by hexokinases, does not induce FAS 
expression in adipose tissue. 2-deoxyglucose, a glucose analogue transported into the 
cell and phosphorylated to 2-deoxyglucose-6-phosphate, mimics the effect of glucose on 
FAS expression. This suggests that glucose-6-phosphate and its metabolites may be the 
signal that mediates the effect of glucose in its regulation of FAS (71). 
Dietary polyunsaturated fatty acids (PUF As) potently inhibit FAS activity and 
expression. Dietary supplement of 2% 18:2 (n-6) to a high carbohydrate/fat free diet 
results in a suppression of hepatic fatty acid synthesis and FAS activity. There was no 
effect when saturated or monounsaturated fatty acids were used (71 ). This inhibitory 
effect has been extended to include all PUFAs of the n-3 and n-6 families (72). 
Growth hormone (GH) and thyroid hormone (T3) also mediate the regulation of 
FAS. GH appears to antagonize the effect of insulin on FAS stimulation. It decreases 
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FAS expression in rats and in cultured pig adipose tissue (73, 74). Thyroid hormone 
stimulates FAS expression. Injection of T 3 into rats for seven days increased FAS 
activity in the liver (75). Moreover, both liver and WAT FAS expression is increased in 
hyperthyroid rats and decreased in hypothyroid rats (76). 
Insulin and glucagon are both involved in the regulation of FAS. FAS expression 
is very low in streptozotocin-diabetic mice, but increases by 2 fold within 1 hr after the 
administration of insulin and 19 fold within 6 hrs after insulin administration (70). In 
contrast, administration of glucagon or dibutyryl cAMP during the refeeding of animals 
previously fasting blocked the elevation of FAS expression (70). These data suggest that 
glucagon, via the elevation of cAMP, antagonizes the stimulation of FAS expression by 
insulin. 
Insulin's stimulatory effect on FAS activity is mediated by a cis-acting insulin 
response element (IRE). The IRE has been identified in the region from -67 to -52 on 
the FAS promoter (77). Additional studies demonstrate that the minimal region (-67 /-52) 
that responds to insulin contains an E box (-65/-60) essential for transcriptional factor 
binding, suggesting that the transcriptional factors that are able to bind to the E box (-65/-
60) may mediate insulin stimulation of FAS expression (78). 
The cellular signaling pathway mediating insulin regulation of FAS is constantly 
being studied. A phosphatidylinositol-3 kinase (PI-3 kinase) inhibitor, wortmannin, has 
been shown to block insulin stimulation of FAS (79). Ectopic expression of constitutive 
active pl  10 subunit of PI-3 kinase increased insulin stimulation of FAS, while 
overexpression of dominant negative p85 subunit suppressed insulin stimulation of FAS 
transcription. Moreover, overexpression of Akt/PKB, a downstream signal of PI-3 
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kinase, stimulated FAS transcription in the absence of insulin (79). These data suggest 
that PI-3 kinase and Akt/PKB are both mediators of insulin stimulation of FAS. 
SREBP 1 mediates insulin stimulation of FAS. FAS promoter contains two 
tandem SREBPl binding sites split by the E box (-65/-60). These sites were first shown 
to mediate sterol modulation of FAS expression (80), but SREBP 1 has also been shown 
to bind to this E box region and activate FAS transcription (81 ). In addition, SREBP 1 
levels decreased during fasting and increased with refeeding of a high carbohydrate diet. 
These observations suggest that SREBP 1 may mediate insulin stimulation of FAS via the 
E box region. 
Angiotensin II, which has been shown to be synthesized and secreted by 
adipocytes, stimulates FAS activity in both 3T3-Ll adipocytes and human adipose tissue 
(82). This effect is mediated by activation of SREBPlc and IRE (83). 
The human homologue of agouti, which is expressed in human adipose tissue, has 
been shown to upregulate adipocyte FAS activity and expression in both 3T3-Ll and 
human adipocytes in a Ca2+-dependent mechanism (84). Agouti stimulation of FAS is 
exerted at the transcriptional level. The effects of agouti and insulin on FAS expression 
are independent and additive. Studies have demonstrated an agouti/Ca2+ response 
element mediating agouti stimulation of FAS transcription in FAS promoter (85). 
B. Lipolysis 
Lipolysis allows for fatty acids stored as TGs to be released and used for energy 
during the fasting state. Released free fatty acids (FF A) are transported in the 
bloodstream bound to albumin and taken up by other tissues. Fatty acids and their 
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derivatives also participate in many events involved in cell signaling and membrane 
biosynthesis. 
Adipocyte lipolysis involves three reactions. The first reaction is the hydrolysis 
of a TAG to a diacylglycerol (DAG). Hormone-sensitive lipase (HSL) catalyzes this 
rate-limit�ng step. HSL also catalyzes the next step in lipolysis, the hydrolysis of a DAG 
to a monoacylglycerol (MAG). The last reaction of lipolysis, the conversion of a MAG 
into glycerol and FFA, is catalyzed by monoglyceride lipase (MGL). While there is no 
evidence of any regulation of MGL, HSL is recognized to be regulated by nutrition and 
hormones (86). Therefore, HSL is a key enzyme in adipocyte metabolism. 
1. Hormone-sensitive lipase (HSL} 
cDNA for HSL has been obtained from both rats and humans (87). The human 
HSL gene is composed of 9 exons, encoding a 775-arnino acid protein. In addition to 
adipose tissue, HSL is also present in steroidogenic tissues such as the heart, muscle, 
adrenal cortex, pancreas, and ovary and testis (88, 89, 90, 91, 92). Regions upstream of 
exon 1 are expressed in a tissue-specific manner, which are either noncoding in adipose 
tissue or encode an N-terminal extension of the enzyme, as in the testis (92) and in the 
pancreas (91 ), leading to a relatively larger species in these tissues. HSL also has a 
significant activity against long chain esters of cholesterol (89). 
HSL protein is composed of an N-terminal domain and a C-terminal catalytic 
domain. The catalytic domain includes a catalytic site, a regulatory module, and a 
putative lipid binding domain (93). The active catalytic triad of HSL consists of Ser-423, 
Asp-703, and His-733 (94). The N-terminal domain is thought to be involved in the 
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interaction of HSL with other cellular proteins, such as fatty acid binding protein (F ABP) 
(95). 
Adipocyte lipolysis is under acute hormonal control. Lipolytic hormones, such as 
catecholamines, act through P-adrenergic receptors, resulting in increases in cAMP. The 
increases in cAMP then activate cAMP dependent protein kinase A (PKA). The 
activation of PKA phosphorylates and activates HSL. Insulin, on the other hand, 
phosphorylates and activates Akt/PKB via the insulin receptor and downstream PI-3 
kinase. PKB phosphorylates and activates phosphodiesterase 3B, an isoform expressed 
in adipose tissue, which in tum catalyzes the degradation of cAMP. The decrease in 
cAMP and PKA activity leads to the inhibition of lipolysis (96, 97). 
HSL is regulated by reversible phosphorylation. It is phosphorylated at two 
distinct serine residues, the regulatory and basal site. PKA phosphorylates HSL at the 
regulatory site (Ser-551 in humans), leading to the activation of HSL (98). The basal site 
(Ser-553 in humans) is phosphorylated by glycogen synthase kinase-4, Ca2+/calmodulin 
dependent kinase II, and 5'-AMP-dependent protein kianse (AMPK) (99). 
Phosphorylation of the basal site prevents the phosphorylation of the regulatory site, thus 
exerting an anti-lipolytic effect (100). Two more serine sites, Ser-659 and Ser-660 in 
rats, have been identified to be phosphorylated by PK.A. Site-directed mutagenesis has 
demonstrated that these two sites are critical in regulating HSL activity ( 101 ). The above 
suggests that HSL is subject to phosphorylation regulation at multiple serine sites. 
The mechanism of HSL activation remains unclear. HSL is decreased 2 to 3 fold 
by PKA in vitro, while a more than 20 fold increase in lipolytic rate occurred in intact fat 
cells in response to hormonal stimulation (96). This may be explained by the 
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translocation of HSL from cytosol to lipid droplets upon isoproterenol stimulation (102, 
103 ). In resting cells, HSL is localized in the cytosol. Upon lipolytic stimulation, HSL 
translocates from the cytosol to the lipid droplets. This is seen in both 3T3-Ll and rat 
adipocytes ( 102, 103). 
Perilipins are proteins found exclusively on the TAG-rich lipid droplets in 
adipocytes and the cholesterol ester-rich droplets in steroidogenic cells (104). They are 
phosphorylated by PKA upon lipolytic stimulation. In addition, it is believed that non­
phosphorylated perilipins impose a barrier to HSL actions that is attenuated by PK.A 
phosphorylation (104). When perilipin constructs were transfected to cells normally 
having small amounts of lipid droplets, perilipins localized to the lipid droplets and the 
intracellular TAG content increased as a result of decreased hydrolysis of lipids (104). 
This data suggests a protective role of perilipins against lipid hydrolysis. Moreover, 
TNF-a exerts a potent lipolytic effect via the inhibition of perilipin expression, leading to 
a reduction of perilipin immunostaining at the droplet surface (104). Overexpression of 
perilipin blocked TNF-a's effect (105), confirming the inhibitory role of non­
phosphorylated perilipin on lipolysis. Phosphorylation of perilipin by PKA results in the 
redistribution of perilipin on lipid droplets. This redistribution altered the structure of the 
lipid droplets surface, allowing HSL to interact with the core TAG in the lipid droplets 
(104 ). Another protein that is involved in HSL translocation and its interaction with lipid 
droplets is lipotransin. Lipotansin is. an HSL-docking protein that may mediate the 
hormonally regulated redistribution of HSL (106). 
Overexpression of HSL in 3T3-Ll adipocytes results in a diminished 
accumulation of TAG (107), confirming HSL's role as a key e�yme in lipolysis. HSL 
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knockout mice exhibit normal body weight, fat mass, and cold sensitivity ( 108). The 
male mice, however, are sterile because of oligospermia. They have normal gonadal and 
adrenal function, but the neutral cholesterol esterhydrolase activity is completely lost in 
the testis. WAT remained unchanged in these animals, and retained 40% of TAG lipase 
activity ( 108). 
2. Nutritional and hormonal regulation of hormone-sensitive lipase 
a. Nutritional regulation 
Nutritional status regulates lipolysis. Prolonged fasting for 3 to 5 days increases 
basal lipolysis rate, HSL activity, protein, and mRNA level in rat adipocytes (109). In 
addition, long-chain fatty acyl CoA and intermediary lipid metabolites, such as palmitoyl 
CoA and oleic acid exert an inhibitory effect on HSL activity (110), reflecting a feed­
back inhibitory mechanism. Studies have shown that F ABP may serve to limit the 
inhibitory effect of intermediary lipid metabolites on HSL activity (95). Ketone bodies 
produced during fasting, vigorous exercise, and uncontrolled diabetes act as potent 
inhibitors of lipolysis (111 ). Thus, ketone bodies, such as acetoacetate and P­
hydroxybutyrate, may be important modulators of lipolysis under the above conditions. 
b. Hormonal regulation 
Catecholamines are powerful regulators of lipolysis that are mediated by four 
adrenergic receptors: PI , p2, P3, and a2 (112). Signals through p receptors result in 
increases in cAMP and stimulation of lipolysis, a2 receptors have the opposite effect on 
lipolysis. It is believed that a.2 receptors predominate in the regulation of adipose tissue 
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lipolysis at rest, and � receptors assume a more important role during stress (1 13) .  Each 
receptor subtype may have a different signaling role. 
Growth hormone (GH) stimulates lipolysis in vitro and at physiological 
concentrations in vivo (1 14, 115). Glucagon and the synthetic glucocorticoid 
dexamethasone also exert potent lipolytic effects in rat adipocytes (114). GH and 
glucagon exert lipolytic effects by stimulating acute HSL activity, while glucocorticoids 
increase lipolysis by stimulating both HSL activity and expression (1 14). 
Tumor necrosis factor-a (INF-a) is produced and secreted by adipose tissue, with 
its production increased in obesity (116). Studies have demonstrated TNF-a as a potent 
lipolytic factor. It stimulates lipolysis by inhibiting perilipin expression. This action was 
confirmed when overexpression of perilipin blocked 'INF-a stimulation of lipolysis 
(117). 
Insulin is by far the most potent anti-lipolytic hormone and has been extensively 
studied. Recent studies demonstrated that lipolysis in normal subjects is sensitive to 
insulin with a half-maximal effect (ED50) occurring at a concentration of 1 2  pM ( 1 1 8). 
However, while insulin acutely inhibits hormone-stimulated lipolysis, chronic exposure 
of rat adipocytes to insulin resulted in stimulated lipolysis and activation of HSL ( 1 1 9). 
This long-term effect of insulin may also contribute the elevation of plasma FF As in 
obesity and diabetes, which are frequently accompanied with hyperinsulinemia and 
insulin resistance. 
Adenosine is also a potent anti-lipolytic factor. Intracellular cAMP is constantly 
exported from adipocytes to extracellular space where it is then converted to adenosine 
by phosphodiesterase and 5' -nucleotidase. Adenosine acts on the A1 adenosine receptor, 
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which inhibits adenylyl cyclase via coupling Gia· This results in a reduction of cAMP 
levels (120). This may represent a transmembrane negative feedback mechanism which 
would limit excess cAMP production, and inhibit lipolysis. 
The major prostaglandins, PGii and PGE2, also exert effects on lipolysis. PGE2 is 
an anti-lipolytic agent, while PGii stimulates lipolysis in rat adipocytes (121). 
III. The Role of Intracellular Ca2+ in Obesity 
A. The role of intracellular Ca2+ in syndrome X 
Obesity is closely related to other metabolic disorders, including insulin 
resistance/hyperinsulinemia, hypertension, and dyslipidemia. These diseases have been 
integrated into a metabolic syndrome referred to as "Syndrome X" (122). Obesity, 
hypertriglyceridemia, hypertension, and insulin resistance/hyperinsulinemia has also been 
termed the "deadly quartet." There is much evidence to demonstrate that all of these 
disorders are characterized by an underlying impairment in intracellular Ca2+ ([Ca2+] i) 
levels. Draznin et al. first reported that obese patients exhibited an elevation in basal 
adipocyte [Ca2+] i (123). Sustained elevations of [Ca2+] i have been observed in 
cardiomyocytes in patients with left ventricular hypertrophy (124), vascular smooth 
muscle cells, platelets, and erythrocytes in patients with hypertension ( 124-128), and 
skeletal muscle cells and adipocytes in patients with insulin resistance (123, 128, 129). 
To explain these tightly interacting abnormalities a unifying "ionic hypothesis" was 
proposed. This hypothesis suggests a common cell lesion underlying these disorders in 
different tissues characterized, in part, by elevations in steady-state intracellular [Ca2+]i 
levels (124). Consistent with this hypothesis, antagonism of Ca2+ influx results in clinical 
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improvements in blood pressure, insulin resistance, platelet aggregation, and left 
ventricular hypertrophy (124). Studies of the mechanisms of agouti-induced obesity also 
indicate that obesity may be partly a manifestation of a lesion in [Ca2+]i regulation (130). 
B. Calcium homeostasis and obesity 
Obesity is associated with alterations in calcium homeostasis . . Of the calcium 
found in plasma, 50% of the calcium is ionized, 35% is bound to albumin, and the 
remaining 15% is complexed with anions. Over half of the calcium found in serum is 
ionized calcium. Only the ionized calcium is biologically active and can be regulated by 
calcium-homeostatic hormones, including PTH, 1,25-(0H)2-D3, and calcitonin. 
Decreased serum ionized calcium, increased urinary calcium excretion, and increased 
calcitrophic hormones PTH and l,25-(0H)2-D3 have been observed in obese humans 
(131-134). While serum calcium levels remain relatively stable, serum albumin, 
phosphate, and bicarbonate levels are decreased in obesity. In addition, serum citrate, 
lactate, fatty acids, and urate levels are increased (132). This causes the concentration of 
less readily resorbable anion in the renal ultrafiltrate, increasing urinary calcium 
excretion, and consequently decreasing serum ionized calcium (135). A decrease in the 
ionized calcium found in the serum stimulates the synthesis and release of calcitrophic 
hormones (132). An inverse correlation has been identified between serum ionized 
calcium levels and BMI (132). However, weight reduction does result in the 
normalization of serum phosphate, bicarbonate, lactate, and fatty acid levels, as well as 
an increase in serum ionized calcium and a decrease in calcitrophic hormone levels (136). 
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C. Intracellular Ca2+ and adipocyte metabolism 
[Ca2Ji plays an important role in the regulation of adipocyte metabolism. Obese 
patients exhibit an elevation in basal adipocyte [Ca2+] i  ( 1 23). This elevation in [Ca2li 
has some physiological consequences that affect lipogenesis and lipolysis. Rat 
adipocytes were treated with A23 l 87, a calcium ionophore, which caused an increase in 
both basal and insulin-stimulated lipogenesis. This action was completely blocked by the 
calcium channel antagonist verapamil and by the calmodulin inhibitor calmidazolium 
(137). [Ca2Ji has also had an inhibitory effect on adipocyte lipolysis. [Ca2+]i modulation 
plays a role in the regulation of both lipolytic and anti-lipolytic actions of hormones in 
adipocytes (138-140). The anitlipolytic effect of epidermal growth factor (EGF) is 
mediated by an increase in [Ca2+] i, The interaction between EGF and [Ca2+] i increases 
the interaction between Gi and adenylyl cyclase, thereby reducing cAMP and inhibiting 
lipolysis (1 39, 1 40). Thyroid hormone modulates lipolysis by increasing [Ca2+] i via 
alterations in phosphodiesterase activity (141 ). In addition, increasing [Ca2+]i by the 
calcium ionophore A23 l 87 in hamster adipocytes stimulates phosphodiesterase activity 
and decreases cAMP levels, resulting in an inhibition of lipolysis ( 142). 
D. Regulation of adipocyte intracellular Ca2+ 
There are many nutritional, hormonal, and pharmacological factors that regulate 
[Ca2+] i. Some of these factors include agouti, calcitrophic hormones PTH and l ,25-
(0H)i-D3, sulfonylureas, angiotensin II, as well as many others. 
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1. Agouti regulation of intracellular Ca2+ 
Agouti was the first obesity gene cloned (143). [Ca2+]i mediated increases in 
lipogenesis and decreases in lipolysis have also been studied in agouti. Avy mice exhibit 
increases in both steady-state [Ca2Ji and Ca2+ influx in several tissues (144, 145). The 
increase in [Ca2Ji is correlated with the degree of ectopic agouti expression and body 
weight (144). Avy mice also exhibit elevated adipocyte fatty acid synthase expression, 
suggesting that adipocyte de novo lipogenesis is increased in this model (146). In 
addition, in vitro studies demonstrate that recombinant agouti protein stimulates dose­
responsive increases in Ca1+ influx and steady-state [Ca2Ji in a variety of cell types, 
including both murine and human adipocytes (144, 145). The physiological 
consequence of this increased [Ca2+]i was explored by studying adipocyte lipogenic genes 
and their activity. Agouti stimulates FAS expression and activity in a Ca2+ -dependent 
manner. This action can be mimicked by Ca1+ channel activation and reversed by Ca2+ 
channel antagonism ( 146). These actions are mediated by an agouti/Ca2+ response 
element on the FAS promoter region (85). Moreover, agouti expression is highly 
correlated with in vivo FAS expression and activity, suggesting that agouti protein, which 
is normally expressed in human adipose tissue, may play a role in human obesity ( 1 47). 
In addition to the effect of agouti on lipogenesis, agouti protein inhibits basal and 
agonist-stimulated lipolysis in human adipocytes via a Ca2+-dependent mechanism (130). 
The mechanism of the anti-lipolytic effect of [Ca2Ji was recently shown to be increased 
[Ca2+]i activation of phosphodiesterase 3B, reducing cAMP levels, and thereby inhibiting 
HSL activity (148). Moreover, agouti regulation of adipocyte [Ca2+]i appears to promote 
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triglyceride accumulation in adipocytes by stimulating lipogenesis and inhibiting 
, lipolysis. 
Agouti acts upon Ca2+ channels through a homology between the carboxyl 
terminus of agouti and ro-conotoxins and plectoxins (149). The antagonism of [Ca2+]i by 
either blocking Ca2+ channels or inhibiting Ca2+ agonists would seem to be a possible 
therapeutic treatment for obesity. Calcium channel blockade has been shown to reduce 
body weight and fat pad mass effectively in several animal models. Treating transgenic 
mice overexpressing agouti with the Ca2+ channel antagonist nifedipine resulted in 
decreases in adipocyte lipogenesis and reduction in fat pad mass ( 150). 
2. Sulfonylurea receptor regulation of intracellular Ca2+ 
Sulfonylureas, such as glibenclamide, are insulin secretagogues used to stimulate 
insulin secretion for the treatment of non-insulin-dependent diabetes mellitus. They bind 
to the sulfonylurea receptor (SUR) of pancreatic �-cells and then block the conductance 
of an ATP-dependent potassium channel (KATP channel) ( 151 ). The attenuation of 
potassium current by blocking this channel depolarizes the �-cells and induces Ca2+ entry 
via L-type calcium channels, causing increased insulin secretion (152, 153). 
Patients treated with glibenclamide frequently experience weight gain. 
Conversely, diazoxide, which inhibits SUR by activating KATP channels, exerts an 
antiobesity effect in obese Zucker rats and hyperinsulinemic, obese humans (154-156). 
The effects of glibenclamide and diazoxide on body weight have been attributed to their 
effect on circulating insulin rather than any direct effect on adipocytes ( 154-15 6). 
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However, it has been demonstrated that human adipocytes express a SUR that mediates 
adipocyte [Ca2+] i signaling (157). 
Adipocytes exhibit a corresponding glibenclamide dose-responsive increase in 
[Ca2+]i. Glibenclamide exerts lipogenic and antilipolytic effects in human adipocytes, 
with significant increases in FAS and GPDH activity and a decrease in glycerol release 
(157). Diazoxide blunted each of the above effects (157). These data suggest that the 
SUR found in human adipocytes regulates [Ca2ii and thereby mediates lipogenesis and 
lipolysis. Consistent with these findings, glibenclamide increased [Ca2+]i in isolated rat 
adipocytes in a dose-dependent manner by stimulating Ca2+ influx through voltage­
dependent Ca2+ channels, with this effect blocked by nitrendipine (123). While more 
studies are needed, these data suggest a potential role for the human SUR in modulating 
energy storage, and therefore obesity. 
3. 1,25-dihydroxyyitamin Di regulation of intracellular Ca2+ 
The active form of vitamin D, l ,25-(0H)2-D3, generates biological responses via 
genomic and non-genomic pathways. l,25-(0H)2-D3 was originally believed to solely 
function via a nuclear receptor in a manner similar to other members of the steroid 
hormone superfamily (158). 1,25-(0H)2-D3 binds to and activates a specific nuclear 
hormone receptor, nVDR. The activated nVDR interacts with another nuclear receptor, 
RXR, and forms a heterodimer complex. This complex functions as a transcriptional 
factor to act on the direct repeat response element named DR-3 in the promoter region of 
certain genes. It either stimulates or suppresses the transcription of these genes (158). 
nVDR knockout mice exhibit impaired bone formation and growth retardation (159, 
39 
160). A high calcium, phosphorous and lactose diet fed at 16 days of age in n VDR 
knockout mice allows normal mineral ion homeostasis, reversing the vitamin D deficient 
phenotype, and suggesting that an alternate pathway may act to preserve intestinal 
calcium absorption and subsequent bone modeling in the absence of a functional n VDR 
(161). It has been shown that l ,25-(0H)2-D3 stimulates intestinal transcaltachia, the 
rapid stimulation of Ca2+ transport into intestinal epithelium, which may contribute to the 
intestinal calcium absorption in these n VDR ablated mice, although might not be 
sufficient to prevent the phenotype of vitamin D deficiency in these mice fed normal 
calcium diets(l 62). 
l,25-(0H)i-D3 also generates rapid, non-genomic signal transduction via a 
membrane vitamin D receptor (m VDR) in a variety of cells (163). It is responsible for 
the modulation of calcium channels, activation of phospholipase and subsequent 
production of DAG and inositol triphosphate, activation of protein kinase C, and 
stimulation of MAP kinase. 1 a,25-dihydroxylumisterol3, a 6-s-cis-locked analog of l ,25-
(0H)2-D3, exerts a non-genomic action, including stimulation of Ca2+ influx, via the 
m VDR (164, 165). An A-ring diasteromer analog of 1,25-(0H)2-D3, 1 P,25-
dihydroxyvitamin D3 , antagonizes the before mentioned action, but has no effects on the 
nVDR (166). 
l ,25-(0H)2-D3 elicits both genomic and non-genomic actions in adipocytes, 
resulting in modulation of lipid and energy metabolism (167-170). It was recently 
demonstrated that 1,25-(0H)2-D3 stimulates adipocyte [Ca2+] i, promotes lipogenesis, and 
inhibits lipolysis in human adipocytes via a rapid non-genomic action (168, 169). These 
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actions were mimicked by la,25-dihydroxylumisterob, a specific mVDR agonist, and 
can be prevented by 1 P,25-dihydroxyvitamin D3, a specific m VDR antagonist. 
In contrast, 1,25-(0H)2-D3, exerts an inhibitory effect on adipocyte uncoupling 
protein-2 (UCP2) expression in human adipocytes independently of the mVDR via 
genomic action ( 1 70) . m VDR agonists and antagonists failed to affect 1 ,25-(0H)2-D3' s 
inhibitory effect on adipocyte UCP2 expression, while n VDR knockout by anti sense 
oligodeoxynucleotide (ODN) prevents the inhibitory effect of l ,25-(0H)i-D3 on 
adipocyte UCP2 expression, demonstrating that the n VDR mediates l ,25-(0H)i-D3 
inhibition of human adipocyte UCP2 expression ( 1 70). 
The role of l ,25-(0H)i-D3 in human obesity is still being explored. nVDR gene 
polymorphism is associated with the susceptibility to obesity in humans with type 2 
diabetes ( 17 1 ). Circulating levels of l ,25-(0H)2-D3 are elevated in obese humans (1 32). 
l ,25-(0H)2-D3 has been shown to stimulate Ca2+ and insulin release in pancreatic P-cells, 
indicating that l ,25-(0H)i-D3, elevated with the disruption of calcium homeostasis 
commonly seen in obese humans, may contribute to the development ofhyperinsulinemia 
via non-genomic action ( 1 72- 1 74). Antagonism of l ,25-(0H)2-D3 may offer new 
interventions for obesity. Suppression of l ,25-(0H)2-D3 levels by increasing dietary 
calcium decreased adipocyte intracellular Ca2+, stimulated lipolysis, inhibited 
lipogenesis, increased adipocyte UCP2 expression and core temperatures in aP2-agouti 
transgenic mice ( 167- 169). The dietary calcium not only attenuated diet-induced obesity, 
but also accelerated weight loss and fat mass reduction secondary to caloric restriction 
( 167- 169). 
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Recent data have demonstrated that this mechanism is relevant to humans. 
Population-based observation of the NHANES III survey revealed that the odds ratio of 
being in the highest body fat quartile was significantly reduced to 0.16 if they were in the 
highest calcium intake quartile (167). In an earlier clinical trial involving the 
antihypertensive effects of dairy products in African-Americans, it was noted that adding 
calcium-rich dairy foods (yogurt) to the diet resulted in a loss of body fat, decreased 
circulating insulin, decreased intracellular calcium, and antihypertensive effects (168). 
More recently, a 6-month clinical trial in obese adults showed that those who consumed a 
calcium-rich ( either from dairy or supplement), hypocaloric diet had greater loss in 
weight and fat mass as compared to those who consumed a low calcium, hypocaloric diet 
(168). Interestingly, increasing dietary calcium caused more fat loss from the abdominal 
region of the body (50% of total fat loss with supplement and 66% loss with dairy) as 
compared to the low calcium diet (19% of total fat loss) (168). Davies et al. (175) 
reported that a significant negative association between calcium intake and body weight 
was observed in two cross-sectional and two longitudinal studies. The odds ratio of 
being overweight was 2.25 for women in the lower half of calcium intakes ( 175). They 
also found a significant weight loss in subjects maintained on a calcium supplement in a 
double-blinded, placebo-controlled, randomized clinical trial ( 17 5). Another study 
exploring the dietary intakes of 53 children showed that the higher the dietary intake of 
calcium, the lower the body fat mass (176). All of these studies support the relationship 
between increased calcium intake and reductions in body weight specific to fat mass in 
both genders, over a wide range of ages, and in many races. 
42 
LITERATURE CITED 
1. Gregoire, F. M., Smas, C. M., and Sul, H. S. (1998). Understanding adipocyte 
differentiation. Physiol. Reviews. 78, 783-809. 
2. Ntambi, J. M., and Kim, Y. (2000). Adipocyte differentiation and gene 
expression. Am. Soc. Nutr. Sci. Suppl, 3122S-3126S. 
3. Burdi, A. R., Poissonnet, C. M., Garn, S. M., Lavelle, M., Sabet, M.D., and 
Bridges, P. ( 1985). Adipose tissue growth patterns during human gestation: a 
histometric comparison ofbuccal and gluteal fat depots. Int. J. Obes. 9, 247-256. 
4. Ailhaud, G., Grimaldi, P., Negrel, R. (1992). Cellular and molecular aspects of 
adipose tissue development. Annu. Rev. Nutr. 12, 207-233. 
5. Cornelius, P., MacDougald, 0. A., and Lane, M. D. (1994). Regulation of 
adipocyte development. Annu. Rev. Nutr. 14, 99-129. 
6. Reznikoff, C. A., Brankow, D. W., and Heidelberger, C. (1973). Establishment 
and characterization of a cloned line of C3H mouse embryo cells sensitive to 
post-confluence inhibition of division. Cancer Res. 33, 3231-3238. 
7. Green, H., and Kehinde, 0. (1975). An established preadipose cell line and its 
differentiation in culture. II. Factors affecting the adipose conversion. Cell. 5, 19-
27. 
8. Negrel, R., Grimaldi, P., and Ailhaud, G. (1978). Establishment ofpreadipocyte 
clonal line from epididymal fat pad of ob/ob mouse that responds to insulin and 
to lipolytic hormones. Proc. Natl. Acad Sci. 75, 6054-6058. 
9. Green, H., and Kehinde, 0. (1979). Formation of normally differentiated 
subcutaneous fat pads by an established preadipose cell line. J. Cell Physio/. 101, 
169-172. 
10. Green, H., and Kehinde, 0. (1974). An established preadipose cell line and its 
differentiation in culture. Cell. 3, 127-133. 
11. Bernlohr, D. A., Angus, C. W., Lane, M. D., Bolanowski, M. A., and Kelly, T. J. 
(1985). Evidence for an increase in transcription of specific mRNAs during 
differentiation of 3T3-Ll preadipocytes. J. Biol. Chem. 260, 5563-5567. 
12. Scott, R. E., Florine, D.L., Willie, J. J., and Yun, K. (1982). Coupling of growth 
arrest and differentiation at a distinct state in the G 1 phase of the cell cycle: Go. 
Proc Natl. Acad. Sci. 79, 845-849. 
43 
44 
13. Erickson, R. L., Longo, K. A., Ross, Hemati, N., and MacDougald, 0. A. (2000). 
Structure and funtion of C/EBPa . Adipocyte Biology and Hormone Signaling. 
IOS Press. 
14. Clarke, S. L., Robinson, C. E., and Gimble, J. M. (1997). CAAT/enhancer binding 
proteins directly modulate transcription from the peroxisome proliferator­
activated receptor gamma 2 promoter. Biochem. Biophys. Res. Commun. 240, 99-
103. 
15. Brun, R. P., Tontonoz, P., Forman, B.M., Ellis, R., Chen, J., Evans, R. M., and 
Spiegalman, B. M. ( 1996). Differential activation of adipogenesis by multiple 
PPAR isoforms. Genes Dev. 10, 974-984. 
16. Soukas, A., Socci, N. D., Saatkamp, B. D., Novelli, S., and Friedman, J. M. 
(2001) Distinct transcriptional profiles of adipogenesis in vivo and invitro. J 
Biol. Chem. 276, 34167-34174. 
17. Fajas, L., Schoonjans, K., Gelman, L., Kim, J. B., Najib, J., Martin, G., Fruchart, 
J. C., Briggs, M., Spiegelman, B. M., and Auwerx, J. ( 1999). Regulation of 
peroxisome proliferator-activated receptor gamma expression by adipocyte 
differentiation and determination factorl /sterol regulatory element binding 
protein! :  implication for adipocyte differentiation and metabolism. Mol. Biol. 
Cell. 19, 5495-5503. 
18. Juge-Aubrey, C. E., Gorla-Bajszczak, A., Pernin, A., Lemberger, T., Wahli, W., 
Burger, A. G., and Meier, C. A. (1995). Peroxisome proliferator-activated 
receptor mediates cross-talk with thyroid hormone receptor by competition for 
retinoid X receptor. J Biol. Chem. 270, 18 117-18122. 
19. Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. B., and Spiegelman, B. M. 
(1994). mPPARy2: Tissue-specific regulator of an adipocyte enhancer. Genes. 
Dev. 8, 1224-1234. 
20. Braissant, 0. F., Foufelle, C., Scotto, M., Dauca, M., and Wahli, W. (1996). 
Differential expression of peroxisome proliferator-activated receptors (PP ARs): 
tissue distribution of PP AR-alpha, -beta, and -gamma in the adult rat. Endocrin. 
137, 354-366. 
21. Morrison, R. F., and Farmer, S. R. (2000). Hormonal signaling and transcriptional 
control of adipocyte differentiation. J Nutr. 1 30, 3 l l 6S-3 l 2 l S. 
22. Lehman, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. 0., Willson, T. 
M., and Kliewer, S. A. (1995). An antidiabetic thiazolodonedione is a high 
affinity ligand for peroxisome proliferator-activated receptor gamma. J. Biol. 
Chem. 270, 12953-12956. 
23. Tontonoz, P., Hu, E., and Spiegelman, B. M. ( 1994). Stimulation of adipogenesis 
in fibroblasts by PPARy2, a lipid-activated transcription factor. Cell. 79, 1 147-
1 156. 
24. Barak, Y., Nelson, M. C., Ong, E. S., Jones, Y. Z., and Ruiz-Lozano, P. ( 1999). 
PP AR gamma is required for placenta, cardiac, and adipose tissue development. 
Mo/. Ce ll. 4, 585-595. 
25. Kuboto, N., Terauchi, Y., Miki, H., Tamemoto, H., and Yamauchi, T. ( 1999). 
PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin 
resistance. Mo/. Cell. 4, 597-609. 
26. Rosen, E. D., Sarraf, P., Troy, A. E., Bradwin, G. and Moore, K. ( 1999). PPAR 
gamma is required for the differentiation of adipose tissue in vivo and in vitro. 
Mo/. Cell. 4, 61 1 -617. 
27. Rosen, E. D., and Spiegelman, B. M. (2000). Molecular regulation of 
adipogenesis. Annu. Rev. Ce ll. Dev. Biol. 16, 145- 17 1 .  
28. Darlington, G. J., Ross, S. E., and MacDougald, 0. A. ( 1998). The role of C/EBP 
genes in adipocyte differentiation. J. B_io /. Chem. 273, 30057-30060. 
29. Yeh, W. C., Cao, Z., Classon, M., and McKnight, S. L. ( 1995). Cascade regulation 
of terminal adipocyte differentiation by three members of the C/EBP family of 
leucine zipper protein. Genes. Dev. 15, 168- 18 1 .  
30. Lin, F. T., and Lane, M. D. ( 1994). CCAT/enhancer binding protein alpha is 
sufficient to initiate the 3T3-Ll adipocyte differentiation program. Proc. Natl. 
Acad. Sci. USA. 91 ,  8757-8761 .  
3 1 .  Freytag, S. 0., Pairlli, D. L., and Gilbert, J. D. ( 1 994). Ectopic expression of the 
CCAT/enhancer binding protein alpha promotes the adipogenic program in a 
variety of mouse fibroblasts. Genes. Dev. 8, 1654- 1663. 
32. Tanaka, T., Yoshida, N., Kishimoto, T., and Akira, S. ( 1997). Defective adipocyte 
differentiation in mice lacking the C/EBP� and/or C/EBPo gene. Embo. J. 16, 
7432-7443. 
33. Wang, N. D., Finegold, M. J., Bradley, A., Ou, C. N., Abdelsayed, S. V., Wilde, 
M. D., Taylor, L. R., Wilson, D. R., and Darlington, G. J. ( 1995). Impaired 
energy homeostasis in C/EBP alpha knockout mice. Science. 269, 1 108- 1 1 12. 
45 
46 
34. Shimomura, L., Shimano, H., Horton, J. D., Goldstein, J. L., and Brown, M. S. 
( 1997). Differential expression of exons 1 a and 1 c in mRNAs for sterol 
regulatory element binding protein-I in human and mouse organs and cultured 
cells. J. Clin. Invest. 99, 838-845. 
35. Tontonoz, P., Kim, J. B., Graves, B. A., and Spiegelman, B. M. (1993). ADDI : A 
novel helix-loop-helix transcription factor associated with adipocyte 
determination and differentiation. Mol. Cell. Biol. 13, 4753-4759. 
36. Brown, M. S., and Goldstein, J. L. (1997). The SREBP pathway: regulation of 
cholesterol metabolism by proteolysis of a membrane-bound transcription factor. 
Cell. 89, 331-340. 
37. Kim, J. B., and Spiegelman, B. M. (1996). ADDl/SREBPl promotes adipocyte 
differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 
10, 1096-1107. 
38. Kim, J. B., Wright, H. M., Wright, M., and Spiegelman, B. M. (1999). 
ADD 1 /SREBP 1 activates PP ARy through the production of endogenous ligand. 
Proc. Natl. Acad Sci. USA 95, 4333-4337. 
39. Girad, J., Perdereau, D., Foufelle, F., Prip-Buss, C., and Ferre, P. (1994). 
Regulation of lipogenic enzyme gene expression by nutrients and hormones. 
FASEB. J. 8, 36-42. 
40. Smith, P. J., Wise, L. S., Berkowitz, R., Wan, C., Rubin, C. S. (1988). Insulin-like 
growth factor- I is an essential regulator of the differentiation of 3T3-Ll 
adipocytes. J. Biol. Chem. 263, 9402-9408. 
41. Benito, M., Porras, A., Nebreda, A. R., and Santos, E. (1991). Differentiation of 
3T3-Ll fibroblasts to adipocytes induced by transfection of ras oncogenes. 
Science. 253, 564-568. 
42. Preston, T., Brownell, H., and Raptis, L. (1997). The timing of insulin/c-ras signal 
is critical for its effect upon the differentiation of C3Hl OTl/2-derived 
preadipocytes. Cancer Letts. 115, 165-171. 
43. Xing, H., Northrop, J. P., Grove, J. R., Kilpatrick, K. E., Su, J. L., and Ringold, G. 
M. (1997). 1NF alpha mediated inhibition and reversal of adipocyte 
differentiation is accompanied by suppressed expression of PP AR gamma 
without effects on pref- I expression. Endocrin. 138, 2776-2783. 
44. Nadler, S. T., Stoehr, J. P., Schueler, K. L., Tanimoto, G., Yandell, B. S., and 
Attie, A. D. (2000). The expression of adipogenic genes is decreased in obesity 
and diabetes mellitus. Proc. Natl. Acad Sci. USA. 91, 11371-11376. 
45. Sul, H. S., Smas, C. M., Chen, L., Mei, B., and Zhao, L. (2000). Pref-I , an 
inhibitor of adipogenesis. Adipose Biology and Hormone Signaling. IOS Press. 
185-199. 
46. Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., and 
· Lehmann, J. M. (1995). A prostaglandin Ji metabolite binds peroxisome 
proliferator-activated receptor gamma and promotes adipocyte differentiation. 
Cell. 83, 813-819. 
47. Miller, C. W., Casimir, D. A., and Ntambi, J. M. (1996). The mechanism of 
inhibition of 3T3-Ll preadipocyte differentiation by prostaglandin F2a1pha· 
Endocrin. 137, 5641-5650. 
48. Kim, S., and Moustaid-Moussa, N. (2000). Secretory, endocrine, and 
auto/paracrine function of the adipocyte. J Nutr. 130, 31108-31158. 
49. Yarwood, S. J., Anderson, N. G., and Kilgour, E. (1995). Cyclic AMP modulates 
adipogenesis in 3T3-F442A cells. Biochem. Soc. Trans. 23, 1758. 
50. Wang, H. Y., and Malbon, C. C. (1996). The Gsa!Gia2 axis control adipogenesis 
independently of adenylyl cyclase. Int. J Obes. 20 (suppl 3), S26-S31. 
51. Gordelaclze, J. 0., Hovik, K. E., Merendino, J. J., Hermouet, S., Gutkind, S., and 
Accili, D. (1997). Effect of activating and inactivating mutation of 08• and Gi2-
alpha protein subunits on growth and differentiation of 3T3-Ll preadipocytes. J. 
Cell. Biochem. 64, 242-257. 
52. Ntambi, J. M., and Takova, T. (1996). Role of Ca2+ in the early stages of murine 
adipocyte differentiation as evidenced by calcium mobilization agents. 
Differentiation. 60, 151-158. 
53. Shi, H., Halvorsen, Y. D., Ellis, P. N., Wilkison, W. 0., and Zemel, M. B. (2000). 
Role of intracellular calcium in human adipocyte differentiation. Physiol. 
Genomics. 3, 75-82. 
54. Soncini, M., Yet, S. F., Moon, Y., Chun, J. Y., and Sul, H. S. ( 1995). Hormonal 
and nutritional control of the fatty acid synthase promoter in transgenic mice. J. 
Biol. Chem. 270, 30339-30343. 
55. Dermot, M. F., Mons, N., and Karpen, J. W. (1995). Adenylyl cyclases and the 
interaction between calcium and cAMP signaling. Nature. 314, 421-424. 
47 
48 
56. Xue, B. Z., Moustaid-Moussa, N., Wilkison, W. 0., and Zemel, M. B. (2001). 
Mechanism of intracellular calcium inhibition of lipolysis in human adipocytes. 
FASEB. J. 15, 2527-2529. 
57. Smas, C. M., and Sul, H. S. (1996). Characterization of pref-I and its inhibitory 
role in adipocyte differentiation. Int. J. Obes. Related Metab. Disorders. 20, 
Suppl. 3, 65S-72S. 
58. Ross, S. E., Hemati, N., Longo, K. A., Bennett, C. N., Lucas, P. C., Erickson, R. 
L., and MacDougald, 0. A. (2000). Inhibition of adipogenesis by Wnt signaling. 
Science. 289, 950-953. 
59. Sul, H. S., and Wang, D. (1998). Nutritional and hormonal regulation of enzymes 
in fat synthesis: studies of fatty acid synthase and mitochondrial glycerol-3-
phosphate acyltransferase gene transcription. Annu. Res. Nutr. 18, 331-351. 
60. Girad, J., Ferre, P., and Foufelle, F. (1997). Mechanisms by which carbohydrates 
regulate expression of genes for glycolytic and lipogenic enzymes. Annu. Res. 
Nutr. 17, 325-352. 
61. Weiss, L., Hoffmann, G. E., Schreiber, R., Andres, H., Fuchs, E., Korber, E., and 
Kolb, H. J. (1986). Fatty acid biosynthesis in man, a pathway of minor 
importance: purification, optimal assay conditions and organ distribution of fatty 
acid synthase. Biol. Chem. 367, 905-912. 
62. Moustaid, N., Jones, B. H., and Taylor, J. W. (1996). Insulin increases lipogenic 
enzyme activity in human adipocytes in primary culture. J. Nutr. 126, 865-870. 
63. Claycombe, K. J., Jones, B. H., Standridge, M. K., Guo, Y., Chun, J. T., Taylor, J. 
W., and Moustaid, N. (1998). Insulin increases fatty acid synthase gene 
transcription in human adipocytes. Am. J. Physiol. 274, R1253-R1259. 
64. Arsland, A., Chinkes, D., and Wolfe, R. R. (1997). Hepatic and whole body fat 
synthesis in humans during carbohydrate overfeeding. Am. J. Clin. Nutr. 65, 
1774-1782. 
65. Chascione, C., Elwyn, D. H., Davila, M., Gil, K. M., Askanazi, J., and Kinney, J. 
M. (1987). Effect of carbohydrate intake on de novo lipogenesis in human 
adipose tissue. Am. J. Physiol. 253, E664-E669. 
66. Guichard, C., Dugail, I., LeLiepvre, X., and Lavau, M. (1992). Genetic regulation 
of fatty acid synthase expression in adipose tissue: overtranscription of the gene 
in genetically obese rats. J. Lipid. Res. 33, 679-687. 
67. Bloch, K., and Vance, D. (1 977). Control mechanisms in the synthesis of 
saturated fatty acids. Annu. Rev. Biochem. 46, 263-298. 
68. Wakil, S. J., Stoops, J. K., and Joshi, V. C. (1 983). Fatty acid synthesis and its 
regulation. Annu. Rev. Biochem. 52, 537-579. 
69. Laksmanan, M. R., Nepokroeff, C. M., and Porter, J. W. (1972). Control of the 
synthesis of fatty acid synthase in rat liver by insulin, glucagon and cAMP. Proc. 
Natl. Acad Sci. USA. 69, 35 16-3519. 
70. Paularskis, J. D., and Sul, H. S. ( 1989). Hormonal regulation of mouse fatty acid 
synthase gene transcription in liver. J. Biol. Chem. 264, 574-577. 
7 1 .  Foufelle, F., Gouhot, B., Egorier, J., Perdereau, D., Girad, J., and Ferre, P. ( 1992). 
Glucose stimulation of lipogenic enzyme gene expression in cultured white 
adipose tissue: a role for glucose-6-phosphate. J. Biol. Chem. 267, 20543-20546. 
72. Clarke, S. D. ( 1994). Dietary polyunsaturated fatty acid regulation of gene 
transcription. Annu. Rev. Nutr. 14, 83-98. 
73. Donkin, S. S., Chiu, P.Y., Yin, D., Louveau, I., and Swencki, B. (1996). Porcine 
somatotropin differentially down-regulates expression of the GLUT4 and fatty 
acid synthase genes in adipose tissue. J. Nutr. 26, 2568-2577. 
74. Donkin, S. S., McNall, A. D., Swencki, B. S., Peters, J. L., and Etherton, T. D. 
( 1 996). The growth hormone-dependent decrease in hepatic fatty acid synthase 
mRNA is the result of a decrease in gene transcription. J. Mo/. Endocrinol. 16, 
15 1 - 158. 
75. Diamant, S., Gorin, E., and Shafrir, E. (1 972). Enzyme activities related to fatty 
acid synthesis in liver and adipose tissue of rats treated with triiodothyronine. 
Eur. J. Biochem. 26, 553-559. 
76. Blennemann, B., Leahy, P., Kim, T. S., and Freake, H. C. (1995). Tissue-specific 
regulation of lipogenic mRNAs by thyroid hormone. Mo/. Cell. Endocrinol. 1 10, 
1-8. 
77. Moustaid, N. Beyer, R. S., and Sul, H. S. ( 1 994). Identification of an insulin 
response element in the fatty acid synthase promoter. J. Biol. Chem. 269, 5629-
5634. 
78. Sul, H. S., Latasa, M. J., Moon, Y., and Kim, K. H. (2000). Regulation of the fatty 
acid synthase promoter by insulin. J. Nutr. 130, 3 l 5S-320S. 
49 
50 
79. Wang, D., and Sul, H. S. (1998). Insulin stimulation of the fatty acid 
synthasepromoter is mediated by the phosphatidylinositol-3 kinase pathway: 
involvement of protein kinase 8/ Akt. J. Biol. Chem. 273, 25420-25426. 
80. Magana, M., and Osborne, T. F. (1996). Two tandem binding sites for sterol 
regulatory element binding proteins are required for sterol regulation of fatty acid 
synthase promoter. J. Biol. Chem. 271, 32689-32694. 
81. Kim, J. 8., Sraf, P., Wright, M., Yao, K. M., Mueller, E., Solanes, G., Lowell, B., 
Spiegelman, B. M. (1998). Nutritional and insulin regulation of fatty acid 
synthase and leptin expression through ADD1/SREBP1. J. Clin. Invest. 101, 1-9. 
82. Saye, J. A., Ragsdale, N. V., Carey, R. M., and Reach, M. J. (1993). Localization 
of angiotensin peptide-forming enzymes of 3T3-F442 adipocytes. Am. J. Physiol. 
264, C 1570-C 1576. 
83. Kim, S. , Dugail, I., Standridge, M. K., Claycombe, K., Chun, J., and Moustaid­
Moussa, N. (200 I ). The angiotensin II response elements is the insulin response 
element in the adipocyte fatty acid synthase gene: the role of the 
ADD1/SREBP1c. Biochem. J. 
84. Jones, B, H., Kim, J. H., Zemel, M. B., Woychik, R. P., Michaud, E. J., Wilkison, 
W. 0., and Moustiad, N. (1996) . .  Upregulation of adipocyte metabolism by 
agouti protein: possible paracrine actions in yellow mouse obesity. Am. J. 
Physiol. 270, El  92-El 96. 
85. Claycombe, K. J., Wang, Y., Jones, B. H., Kim, S., Wilkison, W. 0., Zemel, M. 
B., Chun, J., and Moustaid-Moussa, N. (2000). Transcriptional regulation of the 
adipocyte fatty acid synthase gene by the agouti gene product : interaction with 
insulin. Physiol. Genomics. 
86. Yeaman, S. J. (1990). Hormone-sensitive lipase- a multipurpose enzyme in lipid 
metabolism. Biochem. Biophys. I 052, 288-293. 
87. Holm, C., Kirchgessner, T. G., Svenson, K. L., Fredrikson, G., Nilsson, S., Miller, 
C. G., Shively, J. E., Heinzmann, C., Sparkes, R. C., Mohandas, T., Lusis, A. J., 
Belfrage, P ., and Schotz, M. C. (1998) Hormone-sensitive lipase: sequence, 
expression, and chromosomal localization to 19cent-ql 3.3. Science. 241, 1503-
1506. 
88. Holm, C., Belfrage, P ., and Fredrikson, G. (1997). Immunological evidence for 
the presence of hormone-sensitive lipase in rat tissues other than adipose tissue. 
Biochem. Biophys. Res. Commun. 148, 99-105. 
89. Cook, K. G., Colbran, R. J., Snee, J., and Yeaman, S. J. (1983). Cytosolic 
cholesterol ester hydrolase from bovine corpus luteum. Biochem. Biophys. Acta. 
752, 46-53. 
90. Small, C. A., Garton, A. J., and Yeaman, S. J. ( 1 989). The presence and role of 
hormone-sensitive lipase in heart muscle. Biochem. J. 258, 67-72. 
91. Mulder, H., Holst, L. S., Svenson, H., Degerman, E., Sundler, F., Ahren, B., 
Borsman, P., and Holm, C. ( 1 999). Hormone-sensitive lipase, the rate-limiting 
enzyme in triglyceride hydrolysis, is expressed and active in �-cells. Diabetes. 
48, 228-232. 
92. Holst, S. L., Langin, D., Mulder, H., Laurell, H., Grober, J., Bergh, A., Mohren­
Weiser, H. W., Edgren, G, and Holm, C. (1996). Molecular cloning, genomic 
organization, and expression of a testicular isoform of hormone-sensitive lipase. 
Genomics. 35, 441-447. 
93. Smith, G. M., Garton, A. J., Aitken, A., and Yeaman, S. J. (1996). Evidence for a 
multi-domain structure for hormone-sensitive lipase. FEBS Lett. 396, 90-96. 
94. Holm, C., Davis, R. C., Osterlund, T., Schotz, M. C., and Fredrikson, G. (1994). 
Identification of the active site serine of hormone-sensitive lipase by site-directed 
mutagenesis. FEBS Lett. 344, 234-238. 
95. Shen, W. J., Sridhar, K., Bernlohr, D. A., and Kraemer, F. B. ( 1 999). Interaction 
of rat hormone-sensitive lipase with adipocyte lipid-binding protein. Proc. Natl. 
Acad Sci. USA. 96, 5528-5532. 
96. Langin, D., Holm, C., and Lafontan, M. (1996). Adipocyte hormone-sensitive 
lipase: a major regulator of lipid metabolism. Proc. Nutr. Soc. 55, 93-109. 
97. Holm, C., Langin, D., Manganiello, V ., Belfrage, P ., and Degerman, E. (1997). 
Regulation of hormone-sensitive lipase activity in adipose tissue. Methods. 
Enzymol. 286, 45-67. 
98. Stalfors, P., Bjorgell, P., and Belfrage, P. (1984). Hormonal regulation of 
hormone-sensitive lipase in intact adipocytes: identification of phosphorylate 
sites and effects on the phosphorylation by lipolytic hormones and insulin. Proc. 
Natl. Acad USA. 81, 3317-3321. 
99. Olsson, H., Stralfors, P., and Belfrage, P. (1986). Phosphorylation of the basal site 
of hormone-sensitive lipase by glycogen synthase kinase-4. FEBS. Lett. 269, 
175-180. 
51 
52 
100. Garton, A. J., and Yeaman, S. J. (1990). Identification and role of the basal 
phosphorylation site on homone-sensitive lipase. Eur. J. Biochem. 191, 245-250. 
101. Anthonsen, M., Bonnstrand, L., Werntedt, C., Degerman, E., and Holm, C. 
(1998). Identification of novel phosphorylation sites in hormone-sensitive lipase 
that is phosphorylated in response to isoproterenol and govern activation 
properties in vitro. J. Biol. Chem. 273, 215-221. 
102. Egan, J. J., Greenberg, A. S., Chang, M. K., Wek, S.A., Moos, M. C., and 
Londos, C. (1992). Mechanism of hormone-stimulated lipolysis in adipocytes: 
translocation of hormone-sensitive lipase to the lipid storage droplet. Proc. Natl . 
Acad Sci. USA. 89, 8537-8541. 
103. Clifford, G. M., Londos, C., Draemer, F. B., Vernon, R. G., and Yeaman, S. J. 
(2000). Translocation of hormone-sensitive lipase and perilipin upon lipolytic 
stimulation of rat adipocytes. J. Biol. Chem. 275, 5011-5015. 
104. Londos, , C., Brasaemle, D. L., Schultz, C. J., Segrest, J. P., and Kimmel, A., R. 
(1999). Perlipins, ADRP, and other proteins that associate with intracellular 
neutral lipid droplets in animal cells. Sem. Cell. Dev. Biol. 10, 51-58. 
105. Souza, S. C., Yamamoto, M. T., Franciosa, M. D., Lien, P., and Greenberg, A. S. 
(1998). BRL 49653 blocks the lipolytic actions of tumor necrosis factor-ex. 
Diabetes. 47, 691-695. 
106. Syn, L. J., and Saltiel, A. R. (1999). Lipotransin: a novel docking protein for 
hormone-sensitive lipase. Mo/. Cell. 4, 109-115. 
107. Sztalryd, C., Komaromy, M. C., and Kraemer, F. B. (1995). Overexpression of 
hormone-sensitive lipase prevents triglyceride accumulation in adipocytes. J. 
Clin. Invest. 95, 2652-2661. 
108. Osuga, J. I., Ishibashi, S. Oka, T., Yagyu, H., Tozawa, R., Fujimoto, A., 
Shionoiri, F., Yahagi, N., Draemer, F. B., Tsutsumi, 0., and Yamada, N. (2000). 
Targeted disruption of hormone-sensitive lipase results in male sterility and 
adipocyte hypertrophy, but not obesity. Proc. Natl. Acad. Sci. USA. 97, 787-797. 
109. Sztalrd, C., and Kraemer, F. B. (1994). Regulation of hormone-sensitive lipase 
during fasting. Am. J. Physiol. 266, El 79-E185. 
110. Jepson, C. A., and Yeaman, S. J. (1992) Inhibition of hormone-sensitive lipase 
by intermediary lipid metabolites. FEBS. Lett. 310, 197-200. 
111. Silverberg, J. D., and Miles, J. M. (1992). Effect of ketosis of fatty acid and 
glucose kinetics in humans. Clin. Res. 40, 166A. 
1 12. Carey, G. B. (1 998). Mechanisms regulating adipocyte lipolysis. Skeletal muscle 
metabolism in exercise and diabetes. Plenum Press. l 51-1 10. 
1 1 3 .  Arner, P., Kriegholm, E, Engfeldt, P. , and Bolinder, J. ( 1 990). Adrenergic 
regulation of lipolysis in situ at rest and during exercise. J. Clin. Invest. 85, 893-
898. 
1 1 4. Slavin, B. G., Ong, J. M., and Kem, P. A. (1 994). Hormonal regulation of 
hormone-sensitive lipase activity and m.RNA levels in isolated rat adipocytes. J. 
Lipid Res. 35, 1535- 1541 . 
1 1 5. Boyle, P. J., Avogaro, A., Smith, L., Bier, D. M., Pappu, D. R., Illingworth, D. 
R., and Cryer, P. E. (1 992). Role of GH in regulating nocturnal rates of lipolysis 
and plasma mevalonate levels in normal and diabetic humans. Am. J. Physiol. 
263, E1 68-E1 72. 
1 1 6. Kem, P. A., Saghizadeh, M., Ong, J. M., Bosch, R. J., Deem, R. and Simsolo, R. 
B. ( 1 995). The expression of tumor necrosis factor in human adipose tissue: 
regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. 
Invest. 95, 21 1 1-21 19. 
1 1 7. Souza, S. C., deVargas,L. M., Yamamoto, M. T., Lien, P., Franciosa, M. D., 
Moss, L. G., and Greenberg, A. S. ( 1 998). Overexpression of perilipin A and B 
blocks the ability of tumor necrosis factor a to increase lipolysis in 3T3-Ll  
adipocytes. J. Biol. Chem. 273, 24665-24669. 
1 1 8. Jensen, M. D., Caruso, M., Reiling, V. J., and Miles, J. M. ( 1 989). Insulin 
regulation of lipolysis in nondiabetic and IDDM subjects. Diabetes. 38, 1595-
1601 .  
1 1 9. Kang, E .  S., Betts, D., Fain, J. N., Bahouth, S .  W., and Myers, L .  K. (1 993). 
Chronic exposure of rat fat cells to insulin enhances lipolysis and activation 
partially purified hormone-sensitive lipase. Diabetes. 42, 1 4 15- 1424. 
120. Finnegan, R. B., and Carey, G. B. (1 998). Characterization of cyclic cAMP 
efflux from swine adipocytes in vitro. Obes. Res. 6, 292-298. 
12 1 .  Chatzipanteli, K., Rudolph, S., and Axelrod, L. ( 1 992). Coordinate control of 
lipolysis by prostaglandin E2 and prostacyclin in rat adipose tissue. Diabetes. 4 1 ,  
927-935. 
122. Reaven, G. M. (1 988). Role of insulin resistance in human disease. Diabetes. 37, 
1595- 1607. 
53 
54 
123. Draznin, B., Sussman, K. E., Eckel, R. H., Kao, M., Yost, T., and Sherman, N. 
A. (1988). Possible role of cytosolic free calcium concentrations in mediating 
insulin resistance of obesity and hyperinsulinemia. J. Clin. Invest. 82, 1848-1852. 
124. Resnick, L. ( 1999). The cellular ionic basis of hypertension and allied clinical 
conditions. Prag. Cardiovas. Dis. 42, 1-22. 
1 25. Shehin, S. E., Sowers, J. R., and Zemel, M. B. ( 1989). Impaired vascular smooth 
muscle 45Ca efflux and hypertension in Zucker obese rats. J. Vas. Med. Biol. 1, 
278-282. 
126. Zemel, M. B., Sowers, J. R., and Shehin, S. E. (1990). Impaired Ca2+ metabolism 
associated with hypertension in Zucker obese rats. Metabolism. 39, 704-708. 
127. Resnick, L. M., Gupta, R. K., Bhargava, K. K., Gruenspan, H., Alderman, M. H., 
and Laragh, J. H. ( 1991 ). Cellular ions in hypertension, diabetes, and obesity. 
Hypertension 17, 951-957. 
128 . Barbagallo, M., Gupta, R. K., Bardicef, 0., Bardicef, M., and Resnick, L. M. 
( 1997). Altered ionic effects of insulin in hypertension: Role of basal ion levels 
in determining cellular responsivesness. J. Clin. Endocrin. Metab. 82, 1761-
1765. 
129. Byyny, R. L., Loverde, M., Llotd, S., Mitchell, W., and Draznin, B. (1992). 
Cytosolic calcium and insulin resistance in elderly patients with essential 
hypertension. Am. J. Hypertension. 5, 459-464. 
130. Xue, B., Moustaid-Moussa, N., Wilkison, W. 0., and Zemel, M. B. �1998). The agouti gene products inhibits lipolysis in human adipocytes via a Ca + dependent 
mechanism. FASEB J. 12, 139 1 -1396. 
131. Bell, N. H., Epstein, S., Greene, A., Shary, J., Oexmann, M. J., and Shaw, S. 
(1985). Evidence for alteration of the vitamin D-endocrine system in obese 
subjects. J. Clin. Invest. 76, 370-373. 
132. Andersen, T., McNair, P., Fogh-Andersen, N., Nielson, T. T., Hyldstrup, L., and 
Transbol, I. ( 1986). Increased parathyroid hormone as a consequence of changed 
complex binding of plasma calcium in morbid obesity. Metabolism. 35, 147-151. 
133 . Zamboni, G., Soffiati, M., Giavarina, D., and Tato, L. (1988). Mineral 
metabolism in obese. Acta. Pediatr. Scand. 77, 741 -746. 
134. Kerstetter, J., Caballero, B., O'Brien, K., Wurtman, R., and Allen, L. (1991). 
Mineral homeostasis in obesity: effects of euglycemic hyperinsulinemia. 
Metabolism. 40, 707-713. 
135. Weidner, M. G., and Clowes, G. H. (1960). The role of the kidney in 
hypocalcemia induced by citrate infusion. Surg. Forum. 10, 444-449. 
136. Andersen, T., McNair, P., Hyldstrup, L., Fogh-Andersen, N., Nielson, T. T., 
Astrup, A., and Transbol, I. (1988). Secondary hyperparathyroidism of morbid 
obesity regresses during weight reduction. Metabolism. 37, 425-428. 
137. Avasthy, N., Jeremy, J. Y., and Dandona, P. (1988). The role of calcium in 
mediating phorbol ester-and insulin-stimulated adipocyte lipogenesis. Diabet. 
Res. 9, 91-95. 
138. Siddle, K., and Hales, C. N. (1977). Calcium and lipolysis in adipose tissue: 
effects of ethaedioxybis-( ethylamine )-tetra-acetate (EGTA) and ionophore 
A23187. Biochem. Soc. Trans. 5, 959-962. 
139. Tebar, F., Solely, M., and Ramirez, I. (1996). The anti-lipolytic effects of insulin 
and epidermal growth factor in rat adipocytes are mediated by different 
mechanisms. Endocrinology. 137, 4181-4188. 
140. Tebar, F. Ramirez, I., and Solely, M. (1993). Epidermal growth factor modulates 
the lipolytic action of catecholamines in rat adipocytes: involvement of a Gi 
protein. J. Biol. Chem. 268, 17199-17204. 
141. Goswami, A., and Rosenberg, I. N. (1978). Thyroid hormone modulation of 
epinephrine-induced lipolysis in rat adipocyte: a possible role of calcium. 
Endocrinology. 103, 2223-2233. 
142. Nemecek, G. M. (1978). Stimulation of hamster adipocyte cyclic 3' :5-nucleotide 
phosphodiesterase activity by ionophore A23187 and calcium. J. Cyc. Nucleo. 
Res. 4, 299-230. 
143. Bultman, S. J., Michaud, E. J., and Woychik, R. P. (1992). Molecular 
characterization of the mouse agouti locus. Cell. 71 ,  1195-1204. 
1 44. Kim, J. H., Kiefer, L. L., Woychik, R. P., Wilkison, W. 0., Truesdale, A. Ittoop, 
0., Willard, D., Nichols, J., and Zemel, M. B. (1997). Agouti regulation of 
intracellular cacium: role of melanocortin receptor. Am. J. Physiol. 272, E3 79-
E384. 
145. Zemel, M. B., Kim, J. H., Woychik, R. P., Michaud, E. J., Kadwell, S. H., Patel, 
I. R., and Wilkison, W. 0. (1995). Agouti regulation of intracellular calcium: 
role in the insulin resistance of viable yellow mice. Proc. Natl. Acad. Sci. USA. 
92, 4733-4737. 
55 
56 
146. Jones, B. H., Kim, J. H., Zemel, M. B., Woychik, R. P., Michaud, E. J., 
Wilkison, W. 0., and Moustaid, N. (1996). Upregulation of adipocyte 
metabolism by agouti protein: possible paracrine actions in yellow mouse 
obesity. Am. J. Physiol. 270, E192-EI96. 
147. Xue, B. Z., and Zemel, M. B. (2000). Relationship between human adipose tissue 
agouti and fatty acid synthase. J. Nutr. 1 30, 2478-2481. 
148. Xue, B. Z., Moustaid, N., Wilkison, W. 0. and Zemel, M. B. (200 1 ). Mechanism 
of intracellular calcium inhibition of lipolysis in human adipocytes. FASEB J. 15, 
2527-2529. 
149. Manne, J., Argeson, A.C., and Siracusa, L. D. (1995). Mechanisms for the 
pleitropic effects of the agouti gene. Proc. Natl. Acad. Sci. USA. 92, 4733-4737. 
150. Kim, J. H., Mynatt, R. L., Moore, J. W., Woychik, R. P., Moustaid, N., and 
Zemel, M. B. (1996). The effects of calcium channel blockade on agouti-induced 
obesity. FASEB J. 10, 1646. 
15 1 .  Bryan, L. A., Nichols, C. G., Wechsler, S. W., Clement, J. P., Boyd, A. E., 
Gonzalez, G., Sosa, C. G., Ngut, K., Bryan J., and Nelson, D. A. (1995). Cloning 
of the � cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. 
Science. 268, 423-426. 
152. Bokvist, K., Ammala, C., Ashcroft, F. M., Bergren, P. 0., Larson, 0., and 
Rorsman, P. (1991). Separate process mediate nucleotide-induced inhibition and 
stimulation of the ATP-regulated K+ -channels in mouse pancreatic � cells. Proc. 
R. Soc. London Ser. 243, 139-144. 
153. Gilon, P., Shepherd, R. M., Henquin, J. C., (1993). Oscillations of secretion 
driven by oscillations of cytoplasmic Ca2+ as evidenced in single pancreatic 
islets. J. Biol. Chem. 268, 22265-22268. 
154. Alemzadeh, R., Slonlm, A. E., Zdanowicz, M., and Maturo, J. (1993). 
Modification of insulin resistance by diazoxide in obese Zucker rats. 
Endocrinology. 133, 705-712. 
155. Alemzadeh, R., Jacobs, A. W., and Pitukcheewnont, P. (1996). Antiobesity effect 
of diazoxide in obese Zucker rats. Metab. 45, 334-341. 
156. Alemzadeh, R., Langley, G., Upchurch, L., Smith, P. and Slonim, A. E. (1998). 
Beneficial effect of diazoxide in obese hyperinsulinemic adults. J. Clin. 
Endocrin. Metab. 83, 1 911-1915. 
157. Shi, H., Moustaid, N., Wilkison, W. 0., and Zemel, M. B. (1999). Role of the 
sulfonylurea receptor in regulating human adipocyte metabolism. FASEB J. 13, 
1833-1838. 
158 . DeLuca, H. F ., and Zierold, C. (1995). Mechanisms and functions of vitamin D. 
Nutr. Rev. 56, S4-S 10. 
159. Yoshizawa, T., Handa, Y., Uematsu, Y., Takeda, S., Sekine, K., Yoshihara, Y., 
Kawakami, T., Arioka, K., Sato, H., Uchiyama, Y., Masushige, S., Fukamizu, A., 
Matsumoto, T., and Kato, S. (1997). Mice lacking the vitamin D receptor exhibit 
impaired bone formation, uterine hypoplasia, and growth retardation after 
weaning. NatureGenetics. 16, 391-396. 
160. Li, Y. C., Pirro, A. E., Amling, M., Delling, G., Baron, R., Bronson, R., and 
Demay, M. B. (1997). Targeted ablation of the vitamin D receptor : an animal 
model of vitamin D-dependent rickets type II with alopecia. Proc. Natl. Acad. 
Sci. USA. 94, 9831-9835. 
161. Amling, M., Priemel, M., Holzmann, T., Chapin, K., Rueger, J. M., Baron, R., 
and Demay, M. B. (1999). Rescue of the skeletal phenotype of vitamin D 
receptor ablated mice in the setting of normal mineral ion homeostasis: formal 
histomorphometric and biomechanical analyses. Endocrin. 140, 4982-4987. 
162. Zhou, L. X., Nemere, I., and Norman, A. W. (1992). la,25-(0H)2-D3 analog 
structure-function assessment of the rapid stimulation of intestinal calcium 
absorption. J. Bone. Miner. Res. 7, 457-463. 
163. Fleet, J. C. (1999). Vitamin D receptor: not just in the nucleus anymore. Nutr. 
Rev. 57, 60-62. 
164. Norman, A. W., Okamura, W. H., Hammond, M. W., Bishop, J. E., Dormanen, 
M. C., Boullion, R., V anBaelen, H., Ridall, A. L., Daane, E., Khoury, R., and 
Farach-Carson, M. (1997). Comparison of 6-s-cis- and 6-s-trans- locked analogs 
of 1,25-dihydroxyvitamin D3 indicates that the 6-s-cis conformation is preferred 
for rapid nongenomic biological response and that neither 6-s-cis- or 6-s-trans­
locked analogs are preferred for genomic biological responses. Mo/. Endocrin. 
11, 1518-15 3 1. 
165. Dusso, A. S., Negrea, L., Gunawardhana, S., Lopez-Hilker, S., Finch, J., Mori, 
T., Nishi, Y., Slatopolsky, E., and Brown, A. J. (1991). On the mechanism for the 
selective action of vitamin D analogs. Endocrin. 128, 1687-1692. 
166. Norman, A. W., Nenere, L., Muralidharan, K. R., and Okamura, W. H. (1992). 
1 �,25-dihydroxyvitamin D3 is an antagonist of 1 a,25-dihydroxyvitamin D3 
stimulated transcaltachia. Biochem. Biophys. Res. Com. 189, 1450-1456. 
57 
58 
167. Zemel, M. B., Shi, H., Greer, B., Dirienzo, D., and Zemel, P. (2000). Regulation 
of adiposity by dietary calcium. FASEB J. 14, 1132-1138. 
168. Zemel, M. B. (2003). Mechanisms of dairy modulation ofadiposity. Am. Soc. 
Nutr. Sci. 252S-255S. 
169. Shi, H., Norman, A. W., Okamura, W. H., Sen, A. , and Zemel, M. B. (2001). 
1 a,25-dihydroxyvitamin D3 modulates human adipocyte metabolism via 
nongenomic action. FASEB J. 15, 2751-2753. 
170. Shi, H., Norman, A. W., Okamura, W. H., Sen, A., and Zemel, M. B. (2002). 
1 a,25-dihydroxyvitamin D3 inhibits uncoupling protein 2 expression in human 
adipocytes. FASEB J. 16, 1808-1810. 
171. Ye, W. Z., Reis, A., Dubois-Laforgue, D., Bellanne-Chantelot, C., Timist, J., and 
Velho, G. (2001). Vitamin D receptor gene polymorphisms are associated with 
obesity in type 2 diabetic subjects with early age onset. Eur. J. Endocrin. 145, 
181-186. 
172. Kajikawa, M., Ishida, H., Fujimoto, S., Mukai, E., Nishimura, M., Fujita, J. , 
Tsura, Y., Okamoto, Y., Norman, A. W., and Seino, Y. (1999). An insulinotropic 
effect of vitamin D analog with increasing intracellular Ca2+ concentration in 
pancreatic � cells through nongenomic signal transduction. Endocrinology. 140, 
4706-4712. 
173. Norman, A. W., Frankel, B. J. , Heldt, A. M., and Grodsky, G. M. (1980). 
Vitamin D deficiency inhibits pancreatic secretion of insulin. Science. 209, 823-
825. 
174. Tanaka, Y. , Seino, Y., Ishida, M., Yamaoka, K., Satomura, K., and Yabuchi, H. 
(1986). Effect of 1,25-dihydroxyvitamin D3 on insulin secretion: direct or 
mediated? Endocrinology. 118, 1971-1976. 
175. Davies, K. M., Heaney, R. P., Recher, R. R., Lappe, J. M., Barger-Lux, M. J., 
Rafferty, K., and Hinders, S. (2000). Calcium intake and body weight. J. Clin. 
Endocrin. Metab. 85, 4635-4638. 
176. Carruth, B. R., and Skinner, J. D. (2001). The role of dietary calcium and other 
nutrients in moderating body fat in preschool children. Int. J. Obes. 25, 559-566. 
PART 3 
EFFECTS OF 1,25-DIHYDROXYVITAMIN D3 ON ADIPOCYTE 
DIFFERENTIATION 
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I. Abstract 
Several recent reports from this laboratory demonstrate a regulatory role for 
intracellular Ca2+ ([Ca2+] i) in modulating lipid metabolism in both human and murine 
adipocytes, with increased [Ca2+]i coordinately stimulating lipogenesis and inhibiting 
lipolysis, thereby expanding lipid mass. Further, we have recently demonstrated that 
l ,25-dihydroxyvitamin-D3 [ l  ,25-(0H)2-D3] stimulates adipocyte membrane vitamin D 
receptor (mVDR)-mediated rapid Ca2+ influx into adipocytes, resulting in the stimulation 
of lipogenesis and inhibition of lipolysis. However, increasing [Ca2+]i in the early stages 
of differentiation inhibits human adipocyte differentiation, whereas increasing [Ca2+]i in 
the late stage promotes human adipocyte differentiation. Accordingly, we have 
investigated the role of l,25-(0H)2-D3 in the differentiation of 3T3-Ll  preadipocytes, 
using triglyceride (TG) accumulation and glycerol-3-phosphate dehydrogenase (GPDH) 
as markers. 3T3-Ll preadipocytes were placed in differentiation media upon confluence, 
and exposed to varying amounts (0, lnM, and lOnM) of l ,25-(0H)i-D3 for either one­
hour pulses or for sustained (24 hrs or 48 hrs) amounts of time throughout the 
differentiation process. Exposure to one-hour pulses of lnM l,25-(0H)2-D3 throughout 
differentiation caused modest decreases (31%-38%) in TG accumulation (p<0.0001), 
with one-hour pulse exposure to 1 OnM l ,25-(0H)i-D3 having little to no effect on TG 
accumulation. One-hour pulse exposure to both lnM and 1 OnM l ,25-(0H)2-D3 
suppressed GPDH activity early, but not late in differentiation. Sustained (24-hour) 
exposure to l,25-(0H)i-D3 (lnM and lOnM) inhibited differentiation at 0-24 hrs, with 
decreases in both TG and GPDH of 41-81 % (p<0.0001). Similarly, sustained exposure 
of l ,25-(0H)2-D3 resulted in marked inhibition of GPDH activity and TG accumulation 
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early in differentiation. In contrast, sustained exposure late in differentiation exerted no 
significant effects on either marker of differentiation. PPAR-y and pref- 1  expression 
were also used as markers of differentiation. One-hour pulses of I OnM l ,25-(0H)2-D3 
did not cause any changes in PPAR·y expression compared to control. Sustained 
exposure to l ,25·(0H)2-D3 throughout differentiation decreased PP AR-y expression, 
with a 92% decrease from 0-48h (p<0.0001). One·hour pulses of l,25-(0H)2-D3 had no 
effect on Pref- I expression, with the exception of an increase in expression at 4 7-48 hr 
(p<0.000 1 ). Sustained exposure to lOnM 1,25-(0H)2-D3 at 0-48 hrs, 24-48 hrs and 47-
48 hrs all caused significant increases (125%- 146%) in the expression of Pref- 1  
(p<0.00 I ). Thus, although l ,25-(0H)2"D3 stimulates lipogenesis, inhibits lipolysis and 
increases TG accumulation in mature human and murine adipocytes, it also modestly 
inhibits the differentiation of preadipocytes into mature adipocytes. 
II. Introduction 
Intracellular calcium ([Ca2+]i) plays a key role in the metabolic modifications 
associated with obesity ( 1). Studies involving the mechanisms of agouti gene-induced 
obesity found that [Ca2+]i modulates de novo lipogenesis in both human and murine 
adipocytes. Previous studies show that an increase in [Ca2Ji via receptor or voltage­
mediated calcium channels stimulates the expression and activity of fatty acid synthase 
(FAS), a key enzyme in de novo lipogenesis, thereby causing an increase in lipogenesis 
and a decrease in lipolysis. The resulting triglyceride accumulation leads to adipocyte 
hypertrophy (2). 
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(Ca2+] i  also appears to play a role in the regulation of adipogenesis, a contributing 
factor to both human and murine obesity (3). In order to investigate the specific role of 
calcium, both thapsigargin, a Ca2+ -ATPase inhibitor, and A23 l 87, a calcium ionophore, 
were used as calcium agonists to stimulate an increase in [Ca2li in human preadipocytes. 
Exposure early in differentiation suppressed triglyceride accumulation greatly. However, 
increasing [Ca2+] i  late in differentiation increased triglyceride accumulation. Similar 
results were also seen using KCl and agouti protein as [Ca2Ji agonists (2, 3). Therefore, 
increasing [Ca2+] i  has a biphasic effect on human adipocyte differentiation, with an 
increase early inhibiting differentiation and an increase in the late stages stimulating 
adipocyte differentiation and lipid filling (3). 
Recent studies have introduced a paradox by showing that a decrease in the 
expression of genes normally involved in adipogenesis is associated with obesity and 
diabetes mellitus. White adipose tissue from obese mice exhibited decreased expression 
of genes important in adipocyte differentiation, as compared to the lean controls. Sterol 
responsive element binding protein (SREBP), responsible for positively regulating 
multiple genes coding for lipogenic enzymes, demonstrated a 2.7-fold decrease in 
expression. Several mRNAs that encode proteins involved in lipid metabolism were 
decreased, including glycerol 3-phosphate dehydrogenase and stearoyl CoA desaturase. 
A dedifferentiation was observed in 3T3-Ll adipocytes including a suppression of 
PP ARy and C/EBPa., as well as other lipogenic enzymes in response to tumor necrosis 
factor a and transforming growth factor � (4). 
1,25-dihydroxyvitamin D3 [ l ,25-(0H)2-D3] acts as a calcium agonist (5). Further, 
we have recently demonstrated that l,25-(0H)2-D3 stimulates adipocyte membrane 
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vitamin D receptor (m VDR)-mediated rapid Ca2+ influx into adipocytes, resulting in the 
stimulation of lipogenesis and inhibition of lipolysis (5). This effect was mimicked by 
la,25-(0H)2-lumisteroh, an agonist for the mVDR. These effects were not seen when 
the human adipocytes were pretreated with I P,25-dihydroxyvitamin D3, a specific 
antagonist for mVDR. 1,25-(0H)i-DJ was also shown to increase adipocyte fatty acid 
synthase (FAS), with 1 a,25-(0H)i-lumisteroh having a greater stimulatory effect on FAS 
activity. Pretreatment with 1 P,25-dihydroxyvitamin D3 also prevented the stimulation of 
FAS. 1,25-(0H)2-D3 and la,25-(0H)2-lumisteroh also reduced adipocyte basal lipolysis, 
with 1 P,25-dihydroxyvitamin D3 preventing any inhibition of lipolysis ( 5). In addition, 
Norman et al. (6) demonstrated that la,25-dihydroxylumisteroh acts on the mVDR solely 
to generate non-genomic action in adipocytes, while 1,25-(0H)2-D3 may target both the 
mVDR and the nuclear vitamin D receptor (nVDR) to mediate genomic and non-genomic 
actions which may interact with each other in signal response and, thereby compromise 
the modulation of lipid metabolism. Accordingly, we have investigated the role of 1,25-
(0H)2-D3 in adipogenesis. 
III. Materials and Methods 
A. Culture and differentiation of murine preadipocytes 
3T3-Ll preadipocytes obtained from ATCC were grown in Dulbecco's Modified Eagle 
Medium (DMEM) containing 10% fetal bovine serum (FBS) and 1 % 
penicillin/streptomycin. Confluent cells were differentiated in a standard differentiation 
medium consisting of DMEM supplemented with 10% FBS, I% penicillin/streptomycin, 
isobutylmethylxanthine (IBMX), dexamethasone, and varying amounts of 1,25-(0H)i-D3 
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(0, l nM, 1 OnM) in ethanol. Eight of the treatment groups were subjected to one hour 
pulse exposures to 1,25-(0H)2-D3 (lnM or lOnM). These exposures occurred at 0- l hour 
(h), 23-24 h, 47-48 h, and 71-72 h. Six of the treatment groups were subjected to 
sustained (24 hour) exposures to l,25-(0H)2-D3 (lnM or lOnM) at 0-24 h, 24-48 h, and 
48-72 h. Cells used for gene expression analysis were exposed to O or 1 OnM 1,25-(0H)2-
D3 at the intervals stated above, with the addition of an exposure from O to 48 h of 
differentiation. The cells were allowed to differentiate for 72 hours. The differentiation 
cocktail was changed everyday for every sample to control for pH. The cells incubated 
for 24 hours in DMEM containing 10% FBS and 1 % penicillin/streptomycin before they 
were collected. 
B. Triglyceride content 
The medium was removed from the 3T3-Ll cells. 250uL of homogenization buffer were 
added to each well. The cells were scraped and collected for subsequent sonication. 
Triglyceride accumulation was measured spectrophotometrically at 500nm using a 
triglyceride assay kit (Sigma procedure 336, St.Louis MO). 
C. Glycerol-3-phosphate dehydrogenase (GPDH) activity 
GPDH activity was measured spectrophotometrically. The GPDH buffer solution 
consisted of 1 M triethanolamine, 1 mM �-mercaptoethanol, 25mM 
ethylenediaminetetraacticacid (EDTA), and water. A combination of the GPDH buffer, 
NADH, and the sample/homogenization buffer was allowed to incubate at 37°C for 5 
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minutes. DHAP was added, and the oxidation rate of NADH was read 
spectrophotometrically at 340nm for 5 minutes. 
D. Protein content 
Total protein content was measured for correction purposes by a modified Bradford 
method using Coomassie Blue dye (Pierce, Rockford, IL). 
E. RNA isolation 
Total RNA from 3T3-Ll adipocytes was extracted using a Totally RNA™ total RNA 
isolation kit (Ambion, Austin, TX). Purity and quantity was measured 
spectrophotometrically at 800nm and 200nm and RNA was stored in formamide. 
F. Gene expression 
Gene expression was measured using real time reverse transcription-polymerase chain 
reaction (RT-PCR). Reverse transcriptase occured at 48° C for 30 minutes. Initial 
denaturation occured at 95° C for 10 minutes. It was followed by 40 cycles of 
denaturation at 95° C for 15  seconds and re-annealing and elongation at 60° C for I 
minute. The PPAR-y forward primer, reverse primer, and probe had the following 
sequences: forward primer-(5'-GCCTATGAGCACITCACAAGAAATT-3'), reverse 
primer-(5' -TGCGAGTGGTCTTCCATCAC-3 '), and probe-(5' CAL Red­
TCTGGCCCACCAACITCGGAATCAG-BHQ-2 3'). The sequences for the Pref-1  
forward primer, reverse primer, and probe were as follows: forward primer-(5' -
TTCGGCCACAGCACCTATG-3'), reverse primer-(5'-
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ACATTGTCAGCCTCGCAGAA-3'), and probe (5'CAL Red­
CCACCCTGCGACCCCCAGTATG-BHQ-2 3'). The 18s forward primer, reverse 
primer, and probe had the following sequences: forward primer-(5' -
AGTCCCTGCCCTTTGT ACACA-3 '), reverse primer-(5' -
GATCCGAGGGCCTCACTAAAC-3'), and probe-(5' 6-FAM­
CGCCCGTCGCTACTACCGA TTGG-BHQ-1 3 ')(Biosearch Technologies, Inc. , Novato, 
CA). 
G. DNA content 
Cell density in culture was determined by measuring DNA using CyQuant® cell 
proliferation assay kit (Molecular Probes, Eugene,OR). 
H. Statistical analysis 
SPSS was used for statistical analysis. After normality of distribution was verified, 
analysis of variance (ANOV A) was used to evaluate statistical significance, with 
significantly different group means separated using the least significant different (LSD) 
or Tukey test. All data are expressed as mean ± SE. 
IV. Results 
Triglyceride (TO) accumulation and glycerol-3-phosphate dehydrogenase 
(GPDH) activity were used as markers of differentiation. The data showing exposure to 
one-hour pulses of lnM and lOnM l,25-(0H)2-D3 throughout differentiation was 
inconclusive (Fig. 2, Fig. 3). Sustained (24-hour) exposure to 1,25-(0H)2-D3 (lnM and 
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Figure 2. Effect of treatment with lnM and lOnM 1,25-(0H)2-D3 for one-hour pulses on triglyceride accumulation throughout 3T3-Ll preadipocyte differentiation. Data are 
expressed as % of control ± SE. 
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of control ± SE. 
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I OnM) inhibited differentiation at 0-24 hrs, with decreases in both TG and GPDH of 41-
8 1  % (p<0.0001) (Fig. 4 and Fig. 5). Similarly, sustained exposure of 1,25-(0H)2-D3 
resulted in marked inhibition of GPDH activity and TO accumulation early, but not late, 
in differentiation (Fig. 4 and Fig. 5). In contrast, sustained exposure late in 
differentiation exerted no significant effects on either marker of differentiation (Fig. 4 
and Fig. 5). 
PPAR-y and pref-I  expression were also used as markers of differentiation. One­
hour pulses of 1 OnM 1,25-(0H)2-D3 did not cause any changes in PPAR-y expression 
compared to control (Fig. 6). Sustained exposure to 1,25-(0H)2-D3 throughout 
differentiation decreased PPAR-y expression, with a 92% decrease from 0-48h 
(p<0.0001, Fig. 6). One-hour pulses of 1,25-(0H)2-D3 had no effect on pref- I  
expression, with the exception of an increase in expression at 47-48 hr (p<0.0001, Fig. 
7). Sustained exposure to 1 OnM 1,25-(0H)i-D3 at 0-48 hrs, 24-48 hrs and 48-72 hrs all 
caused significant increases ( 125%-146%) in the expression of Pref- I  (p<0.001, Fig. 7). 
The DNA measurement data demonstrate that there were similar concentrations of 
cells in both types of plates used for the experiments. While there are some differences 
in the amount of DNA found in the 24-well plates (Table 1), none of the amounts are 
significantly different from control, and there are no significant differences among the 
treatments in the 6-well plates (Table 2). 
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Table 1 .  DNA Measurement Data for 24-well Plates 
Concentration of 1 ,25-(0H)2-D3 and 24-well plates (TG and GPDH) 
Time of Treatment 
Control 
lnM 0-1 h 
lOnM 0-1 h 
lnM 0-24 h 
lOnM 0-24 h 
lnM 23-24 h 
lOnM 23-24 h 
lnM 24-48 h 
lOnM 24-48 h 
lnM 47-48 h 
lOnM 47-48 h 
lnM 48-72 h 
lOnM 48-72 h 
lnM 71-72 h 
lOnM 71-72 h 
DNA u2/sample 
.090 ± .003a,o,c 
.099 ± .003°'c 
.098 ± .003a,o,c 
.093 ± .005a,o,c 
. 1 04 ± .004c 
, 094 ± , 003 a,b,C 
. 1 01  ± .002c 
. 1 02 ± .002c 
.088 ± .003a,D,C 
.088 ± .002a,o,c 
.089 ± .003a,o,c 
.092 ± .005a,b,C 
.084 ± .002a,o 
.082 ± .004a 
.081 ± .004a 
�b,c Non-similar superscripts within columns indicate significant differences at p<0.05 . 
Values are Mean ± SE. 
Table 2. DNA Measurement Data for 6-well Plates 
Concentration of D3 and Time of 6-well plates (Gene Expression) 
Treatment 
Control 
lOnM 0-1 h 
lOnM 0-24 h 
lOnM 0-48 h 
10nM 23-24 h 
10nM 24-48 h 
lOnM 47-48 h 
lOnM 48-72 h 
lOnM 71-72 h 
*No significant differences among groups at p<0.05 . 
Values are Mean ± SE. 
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DNA uwsample* 
. 1 73 ± .008 
. 1 9 1  ± .02 1 
.228 ± .0 1 3  
.223 ± .0 12  
.2 1 1  ± .0 1 1  
.2 1 7  ± .008 
.21 7  ± .01 5 
.21 6  ± .003 
. 1 82 ± .007 
V. Discussion 
We have recently demonstrated that increasing [Ca2+] i has a biphasic effect on 
adipogenesis, inhibiting the early stages and accelerating late differentiation and lipid 
filling (3). We have also reported that l ,25-(0H)2-D3 stimulates rapid adipocyte [Ca2J i 
influx via a membrane vitamin D receptor (mVDR) (5). Accordingly, it may be 
anticipated that l ,25-(0H)2-D3 will have similar effects on markers of differentiation as 
other Ca2+ agonists. However, although our data does demonstrate an inhibitory effect of 
early exposure to l ,25-(0H)2-D3, late exposure to l ,25-(0H)2-D3 did not stimulate 
differentiation or lipid filling. Accordingly, it is likely that in addition to m VDR­
mediated [Ca2Ji influx affecting adipogenesis, nuclear vitamin D receptor (nVDR) 
signaling may modify these effects. 
l ,25-(0H)2-D3 was originally believed to solely function via a nuclear receptor in 
a manner similar to the other members of the steroid hormone superfamily (8). However, 
l ,25-(0H)2-D3 may target both m VDRs and n VD Rs to mediate genomic and non­
genomic actions which may interact with each other in signal response and, thereby affect 
the modulation of lipid metabolism. For example, l,25-(0H)2-D3 generates rapid, non­
genomic signal transduction, including modulation of calcium channels, via a m  VDR (5, 
9). 1,25-(0H)2-D3 stimulates adipocyte [Ca2Ji, promotes lipogenesis, and inhibits 
lipolysis via this non-genomic action (5). However, l,25-(0H)i-D3 generates genomic 
acti_ons via binding to a specific nVDR (10). l,25-(0H)2-D3 exerts an inhibitory effect on 
adipocyte uncoupling protein 2 (UCP2) expression via n VDR-mediated genomic action 
(10). 
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l ,25-(0H)2-D3 binds to and activates a specific nuclear hormone receptor, nVDR. 
The activated n VDR then interacts with another nuclear receptor, retinoid X receptor 
(RXR), and forms a heterodimer complex. This complex functions as a transcriptional 
factor to act on the direct repeat response element, DR-3, in the promoter region of target 
genes, thereby stimulating or suppressing transcription of those genes encoding for 
proteins that carry out a variety of functions (5). The ablation of the (RXR) gene in 
adipocytes of transgenic mice caused a delay in the formation of fat depots and a 
resistance to dietary and chemically induced obesity (11 ). In addition, multiple studies 
(12, 13) suggest that retinoic acid inhibits adipogenesis by blocking the induction of/ 
inhibiting the expression of PP AR-y. Sato et al. ( 14) also demonstrated an inhibitory 
effect of 1,25-(0H)2-D3 on the differentiation of 3T3-Ll cells by demonstrating an 
inhibition of triacylglycerol accumulation. Accordingly, our data suggest that early 
exposure to lower doses of 1,25-(0H)i-D3 may result in mVDR-mediated inhibition of 
differentiation, while higher doses and/or later exposure may result in nVDR-mediated 
events. 
Alternatively, the discrepancy between the findings may be due to the source of 
the cells. Ntambi et al. (15) also did not find a stimulatory effect of increasing [Ca2+]i in 
the late stages of differentiation in 3T3-Ll cells. 3T3-Ll cells are derived from mouse 
embryos (16), while the human preadipocytes used by Shi et al. (3) originated from 
human stromal-vascular cells in the subcutaneous fat depot. Cell models derived from 
different species and of different developmental stages may exhibit distinct 
differentiation properties. 
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The normal physiological level of l ,25-(0H)2-D3 is :SO. lnM, but past studies 
demonstrated that differentiation of 3T3-LI preadipocytes is not affected at this 
concentration of l ,25-(0H)2-D3 (14). The reason why preadipocytes require a high dose 
of l ,25-(0H)2-D3 to exert its inhibitory effect on differentiation is unclear. However, in 
addition to the differences between cell lines and adipose tissue, one possible reason 
could be the presence of serum in the culture media causing a reduction in the affinity of 
the receptor for l ,25-(0H)i-D3. 
In summary, the TO and GPDH data suggest that l ,25-(0H)2-D3 may modestly 
inhibit adipocyte differentiation when exposed early in differentiation, but has no effect 
late in differentiation. Sustained exposure to l ,25-(0H)2-D3 throughout differentiation 
decreased PPAR-y expression, and increased pref- I  expression. However, one-hour 
pulses had no effect on the expression of PPAR-y or pref- I .  
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SUMMARY AND CONCLUSIONS 
Regulation of adipocyte differentiation and metabolism via l ,25-(0H)2-D3 
signaling pathways may play an important role in the development of obesity in vivo. 
Several lines of evidence demonstrate that the circulating level of l ,25-(0H)2-D3 is 
elevated in obese humans. Suppression of l ,25-(0H)2-D3 by increasing dietary calcium 
decreases adipocyte intracellular ca2+, stimulates lipolysis, inhibits lipogenesis, and 
increases UCP2 expression in transgenic mice, thereby reducing body weight and fat 
mass in these animals. Similar effects have also been observed in recent clinical trials. 
Accordingly, it is important to understand the role of l ,25-(0H)2-D3 both in adipocyte 
metabolism as well as the differentiation of preadipocytes to adipocytes. 
Previous data demonstrate that agents which increase adipocyte cytosolic Ca2+ 
stimulate lipogenesis, inhibit lipolysis, and increase triglyceride accumulation. Our data 
demonstrate that l,25-(0H)i-D3 has a similar effect as other Ca2+ agonists when used in 
low doses early in differentiation, while higher doses and late exposure do not mimic 
these effects. Accordingly, we propose that the effects of low doses early in 
differentiation are mediated via the membrane vitamin D receptor (m VDR) and increases 
in [Ca2+]i. However, higher doses of l,25-(0H)i-D3 and/or late exposure during 
differentiation may exert a counter-regulatory effect which is mediated via the nuclear 
vitamin D receptor (n VDR). More research is needed to fully understand the role of 
l ,25-(0H)i-D3 and its various receptors on adipocyte differentiation and metabolism. 
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